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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 77, Revision 2 
(FGE.77Rev2): Consideration of Pyridine, Pyrrole and Quinoline 
Derivatives evaluated by JECFA (63rd meeting) structurally related to 
Pyridine, Pyrrole, Indole and Quinoline Derivatives evaluated by EFSA in 
FGE.24Rev2 (2013)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA), and to decide whether further evaluation is 
necessary, as laid down in Commission Regulation (EC) No 1565/2000. The present consideration concerns a 
group of 22 pyridine, pyrrole and quinoline derivatives evaluated by JECFA (63rd meeting). The revision of this 
consideration is made since additional toxicity data have become available for 1-furfurylpyrrole [FL-no: 13.134]. 
The data are intended to cover the re-evaluation of this substance and 2-acetyl-1-ethylpyrrole [FL-no: 14.045] 
and 2-acetyl-1-methylpyrrole [FL-no: 14.046]. The Panel concluded that for 6-methylquinoline [FL-no: 14.042], 
the genotoxicity data available do not clear the concern with respect to genotoxicity in vitro and accordingly the 
substance is not evaluated through the Procedure. For 21 substances [FL-no: 13.134, 14.001, 14.004, 14.007, 
14.030, 14.038, 14.039, 14.041, 14.045, 14.046, 14.047, 14.058, 14.059, 14.060, 14.061, 14.065, 14.066, 14.068, 
14.071, 14.072 and 14.164] considered in this FGE, the Panel agrees with the JECFA conclusion, “No safety 
concern at estimated levels of intake as flavouring substances” based on the MSDI approach. Besides the safety 
assessment of these flavouring substances, the specifications for the materials of commerce have also been 
evaluated, and the information is considered adequate for all the substances. 
© European Food Safety Authority, 2015 
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SUMMARY  
Following a request from the European Commission the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific advice to the 
Commission on the implications for human health of chemically defined flavouring substances used in 
or on foodstuffs in the Member States. In particular, the CEF Panel was requested to consider the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) evaluations of flavouring substances 
assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in 
Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, 
which was adopted by Commission Decision 1999/217/EC and its consecutive amendments. 
The Flavouring Group Evaluation 77 concerns the EFSA consideration of 22 flavouring substances 
from a group of pyridine, pyrrole and quinoline derivatives evaluated by JECFA at their 63rd meeting.  
This revision two of FGE.77 is made due to the submission of new toxicity data requested in previous 
versions of FGE.77. The data are a new 90-day toxicity study with 1-furfurylpyrrole [FL-no: 13.134]. 
As the Panel consider 1-furfurylpyrrole a representative for 2-acetyl-1-ethylpyrrole [FL-no: 14.045] 
and 2-acetyl-1-methylpyrrole [FL-no: 14.046], the new data will also cover the evaluation of these two 
substances. 
The present consideration therefore concerns these additional data and will be considered in relation to 
the European Food safety Authority (EFSA) evaluation of 24 pyridine, pyrrole, indole and quinoline 
derivatives evaluated in the Flavouring Group Evaluation 24, Revision 2 (FGE.24Rev2).  
JECFA evaluated two substances [FL-no: 13.134 and 14.030] via the B-side of the Procedure and 20 
substances via the A-side. 
The Panel agrees with the way the application of the Procedure has been applied by JECFA for four of 
the 22 substances. Three of these four substances, methyl nicotinate [FL-no: 14.071], indole [FL-no: 
14.007] and 3-methylindole [FL-no: 14.004], were evaluated by JECFA on the A-side of the 
Procedure, as they were anticipated to be metabolised to innocuous products. For these three 
substances, EFSA agreed no safety concern at step A3 of the Procedure, as the intake is below the 
threshold of the structural class. For the fourth substance, 2-pyridine methanethiol [FL-no: 14.030], for 
which EFSA agrees with JECFA that it should be evaluated through the B-side of the Procedure, a 
NOAEL was derived from a 90-day study. 
The Panel concluded, contrary to JECFA, that 6-methylquinoline [FL-no: 14.042] (evaluated via the 
B-side by JECFA) should not be evaluated through the Procedure due to concern with respect to 
genotoxicity in vitro. 
Also for 1-furfurylpyrrole [FL-no: 13.134], EFSA disagree with JECFA, as the 90-day feeding study 
in rats was considered a poorly reported old study, the quality of which cannot be assessed. 
For the remaining 16 substances the Panel, in contrast to JECFA, did not anticipate that they will be 
metabolised to innocuous products and accordingly concluded that they should be evaluated along the 
B-side of the Procedure. However, in FGE.77, for 10 [FL-no: 14.038, 14.039, 14.058, 14.059, 14.060, 
14.061, 14.065, 14.066, 14.072 and 14.164] of these 16 JECFA-evaluated pyridine derivatives 
evaluated via the B-side of the Procedure by EFSA, NOAELs could be derived to provide adequate 
margins of safety and the Panel agrees with the JECFA conclusion “no safety concern at estimated 
levels of intake as flavouring substances” based on the MSDI approach. 
In FGE.77 it was concluded that for pyrrole and the five pyrrole derivatives as well as for isoquinoline 
[FL-no: 13.134, 14.001, 14.041, 14.045, 14.046, 14.047 and 14.068], No Observed Adverse Effect 
Levels (NOAELs) could not be derived for the substances themselves or for structurally related 
substances. Accordingly, additional toxicological data were required for these seven substances. 
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Since the publication of FGE.77, three 90-day studies were provided for isoquinoline [FL-no: 14.001], 
pyrrole [FL-no: 14.041] and 2-acetylpyrrole [FL-no: 14.047]. These three studies were evaluated in 
FGE.77Rev1 and NOAELs to provide adequate margin of safety were derived to cover the three 
substances as well as the structurally related 2-propionylpyrrole [FL-no: 14.068]. 
Since publication of FGE.77Rev1, a 90-day study has become available for 1-furfurylpyrrole [FL-no: 
13.134] and an NOAEL to provide adequate margin of safety is derived to cover this substance as well 
as the structurally related 2-acetyl-1-ethylpyrrole [FL-no: 14.045] and 2-acetyl-1-methylpyrrole [FL-
no: 14.046]. 
So, in total, for 18 substances [FL-no: 13.134, 14.001, 14.030, 14.038, 14.039, 14.041, 14.045, 14.046, 
14.047, 14.058, 14.059, 14.060, 14.061, 14.065, 14.066, 14.068, 14.072 and 14.164], evaluated via the 
B-side of the Procedure by EFSA, NOAELs could be derived to provide adequate margins of safety. 
In order to determine whether the conclusion for the 22 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity tests are available for the 22 JECFA- 
evaluated substances. 
Thus, for one substance, 6-methylquinoline [FL-no: 14.042], the Panel concluded that the Procedure 
should not be applied until adequate genotoxicity data become available. For the remaining 21 JECFA 
evaluated pyridine, pyrrole and quinoline derivatives [FL-no: 13.134, 14.001, 14.004, 14.007, 14.030, 
14.038, 14.039, 14.041, 14.045, 14.046, 14.047, 14.058, 14.059, 14.060, 14.061, 14.065, 14.066, 
14.068, 14.071, 14.072 and 14.164] the Panel agrees with the JECFA conclusion “no safety concern at 
estimated levels of intake as flavouring substances” based on the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 20084 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/20125. The list includes flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20006. 
EFSA concluded in FGE.77Rev1 that three substances [FL-no: 13.134, 14.045 and 14.046] should not 
be evaluated through the Procedure as no adequate toxicity study was available from which a no 
observed adverse effect level (NOAEL) could be established, neither on the substances nor on 
supporting substances.  
Information on 1-furfurylpyrrole [FL-no: 13.134] has been submitted by the European Flavour 
Association. The information is intended to cover the re-evaluation of this substance and 2-acetyl-1-
ethylpyrrole [FL-no: 14.045] and 2-acetyl-1-methylpyrrole [FL-no: 14.046]. 
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substance. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
The European Commission requests EFSA to carry out a safety assessment on the following three 
substances: 1-furfurylpyrrole [FL-no: 13.134], 2-acetyl-1-ethylpyrrole [FL-no: 14.045] and 2-acetyl-1-
methylpyrrole [FL-no: 14.046], in accordance with Commission Regulation (EC) No 1565/2000. 
                                                     
4
  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. Official Journal of the European 
Communities 31.12.2008, L 354/34-50. 
5 
 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances 
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to 
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) 
No 1565/2000 and Commission Decision 1999/217/EC. Official Journal of the European Communities 2.10.2012, L 267, 
1-161.OJ L 267, 2.10.2012, p. 1. 
6
  Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. Official Journal of the European Communities 
19.7.2000, L 180, p. 8-16. 
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ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000, hereafter named the “EFSA Procedure”. This Procedure 
is based on the opinion of the Scientific Committee on Food (SCF, 1999), which has been derived 
from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the “JECFA 
Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be evaluated through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by JECFA only on the basis of these 
figures. For Register substances for which this is the case the Panel will need EU production figures in 
order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that JECFA, at its 65th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006b). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by JECFA or has 
not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by JECFA. The Panel will need information on use 
levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by JECFA 
JECFA uses the threshold of concern of 1.5 microgram (µg)/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
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Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg per person per 
day would not be expected to present a safety concern. The Committee recommended that the 
Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended 
to include the last step on the right-hand side of the original procedure (“Do the condition of use result 
in an intake greater than 1.5 µg per day?”)” (JECFA, 1999).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 µg per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro, 
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
1. History of the Evaluation of the Substances in the Present FGE  
JECFA has evaluated a group of 22 flavouring substances consisting of pyridine, pyrrole and 
quinoline derivatives (JECFA, 2006a). 
These 22 substances were considered by EFSA in FGE.77, in which the Panel concluded that 
additional toxicity data were needed for seven substances [FL-no: 13.134, 14.001, 14.041, 14.045, 
14.046, 14.047 and 14.068] as no adequate toxicity studies were available from which a No Observed 
Adverse Effect Level (NOAEL) could be established, neither on the substances nor on supporting 
substances. The Panel also concluded, contrary to JECFA, that 6-methylquinoline [FL-no: 14.042] 
should not be evaluated through the Procedure due to concern with respect to genotoxicity in vitro. 
In the first Revision of FGE.77, FGE.77Rev1, additional toxicity data were provided for isoquinoline 
[FL-no: 14.001], pyrrole [FL-no: 14.041] and 2-acetylpyrrole [FL-no: 14.047]; the toxicity data on 2-
acetylpyrrole also cover 2-propionylpyrrole [FL-no: 14.068]. The main studies provided were for each 
substance a 90-day study. Further, additional genotoxicity data for 6-methylquinoline [FL-no: 14.042] 
became available. EU production volumes were provided for four substances, [FL-no: 14.045, 14.058, 
14.059 and 14.164] for which the evaluation could not be finalised, due to lack of these data. Based on 
these newly submitted EU production volumes (IOFI, 2013), the substances were already evaluated in 
FGE.967 (EFSA CEF Panel, 2011), but for the sake of completion, the information was also included 
here as well. Finally, information on solubility was provided for six substances [FL-no: 13.134, 
14.007, 14.030, 14.038, 14.045 and 14.046] since the previous evaluation of FGE.77. 
                                                     
7
  Consideration of 88 flavouring substances considered by EFSA for which EU production volumes / anticipated production 
volumes have been submitted on request by DG SANCO. 
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FGE Opinion adopted 
by EFSA 
Link No. of 
candidate 
substances 
FGE.77 31 January 2008 http://www.efsa.europa.eu/en/efsajournal/pub/936.htm 22 
FGE.77Rev1 19 February 2014 http://www.efsa.europa.eu/en/efsajournal/pub/3586.htm 22 
FGE.77Rev2 2014  22 
The present revision of FGE.77, FGE.77Rev2, includes additional toxicity data, among which an oral 
90-day study provided for 1-furfurylpyrrole [FL-no: 13.134]. The data are intended to cover the re-
evaluation of this substance as well as 2-acetyl-1-ethylpyrrole [FL-no: 14.045] and 2-acetyl-1-
methylpyrrole [FL-no: 14.046]. A search in open literature was conducted for metabolism, 
genotoxicity and toxicity for 1-furfurylpyrrole. This search did not reveal any pertinent new 
information on the substance.  
2. Presentation of the Substances in the JECFA Flavouring Group 
2.1. Description 
2.1.1. JECFA Status 
JECFA has at the 63rd meeting evaluated a group of 22 flavouring substances consisting of pyridine, 
pyrrole and quinoline derivatives (JECFA, 2005b; JECFA, 2006a). 
2.1.2. EFSA Considerations 
The Panel concluded that all the substances in the JECFA flavouring group of pyridine, pyrrole and 
quinoline derivatives are structurally related to the group of pyridine, pyrrole, indole and quinoline 
derivatives from chemical group 28 evaluated by EFSA in the Flavouring Group Evaluation 24, 
Revision 2 (FGE.24Rev2) (EFSA CEF Panel, 2013). 
2.2. Isomers 
None of the 22 flavouring substances in the group of pyridine, pyrrole and quinoline derivatives has 
possibility for stereoisomerism. 
2.3. Specifications 
2.3.1. Status 
The JECFA specifications are available for all 22 substances (JECFA, 2005a) (see Table 1).  
2.3.2. EFSA Considerations 
The specifications are considered adequate for all 22 substances. 
3. Intake Estimation 
3.1. Status 
For all 22 substances, evaluated through the JECFA Procedure, production volumes, based on which 
MDSI values can be calculated, are available for the EU (see Table 8). 
3.2. EFSA Considerations 
For one substance [FL-no: 14.041], the Industry has submitted food categories8 and use levels in these 
for normal and maximum use (EFFA, 2012) (see Table 10, Appendix A). Based on the normal use 
                                                     
8
  Annex III, Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of 
an evaluation programme in application of Regulation (EC) No 2232/96. Official Journal of the European Communities 
19.7.2000, L 180, p. 8-16. 
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levels the mTAMDI value can be calculated (see Table 11, Appendix A). The mTAMDI value for 
[FL-no: 14.041], is below the threshold of concern of 1800 µg/person/day for a structural class I 
substance. For the remaining 21 substances, use levels are needed to calculate the mTAMDIs. 
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SUMMARY OF SPECIFICATION DATA 
Table 1:  Summary of Specification Data (JECFA, 2005a) 
FL-no 
JECFA
-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index (d) 
Spec.gravity (e) 
EFSA comments 
13.134 
1310 
1-Furfurylpyrrole N O
 
3284 
2317 
1438-94-4 
Liquid 
C9H9ON 
147.18 
Insoluble 
Soluble 
76-78 (1 hPa) 
 
NMR 
98 % 
1.529-1.536 
1.078-1.084 
 
 
14.001 
1303 
Isoquinoline N
 
2978 
487 
119-65-3 
Solid 
C9H7N 
129.16 
Slightly 
soluble 
Soluble 
242-243 
27-29 
NMR 
97 % 
1.621-1.627 
1.097-1.103 
 
 
14.004 
1304 
3-Methylindole HN
 
3019 
493 
83-34-1 
Solid 
C9H9N 
131.18 
Soluble 
Soluble 
 
95-97 
NMR 
97 % 
n.a. 
n.a. 
 
 
14.007 
1301 
Indole HN
 
2593 
560 
120-72-9 
Solid 
C8H7N 
117.15 
Insoluble 
Soluble 
n.a. 
51-54 
NMR 
97 % 
n.a. 
n.a. 
 
 
14.030 
1308 
2-Pyridine 
methanethiol 
SH
N
 
3232 
2279 
2044-73-7 
Liquid 
C6H7NS 
125.20 
Soluble 
Soluble 
57-58 (0.8 hPa) 
 
NMR 
98 % 
1.573-1.580 
1.150-1.157 
 
 
14.038 
1309 
2-Acetylpyridine 
N
O
 
3251 
2315 
1122-62-9 
Liquid 
C7H7ON 
121.14 
Insoluble 
Soluble 
189-193 
 
IR NMR 
97 % 
1.518-1.524 
1.077-1.084 
 
 
14.039 
1316 
3-Acetylpyridine N
O
 
3424 
2316 
350-03-8 
Liquid 
C7H7ON 
121.14 
Soluble 
Soluble 
230 
 
NMR 
97 % 
1.530-1.540 
1.103-1.112 
 
 
14.041 
1314 
Pyrrole HN
 
3386 
2318 
109-97-7 
Liquid 
C4H5N 
67.09 
Slightly 
soluble 
Soluble 
130-131 
 
IR 
98 % 
1.507-1.510 
0.955-0.975 
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Table 1:  Summary of Specification Data (JECFA, 2005a) 
FL-no 
JECFA
-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index (d) 
Spec.gravity (e) 
EFSA comments 
14.042 
1302 
6-Methylquinoline N
 
2744 
2339 
91-62-3 
Liquid 
C10H9N 
143.19 
Slightly 
soluble 
Soluble 
259 
 
NMR 
98 % 
1.611-1.617 
1.060-1.066 
 
 
14.045 
1305 
2-Acetyl-1-
ethylpyrrole N
O
 
3147 
11371 
39741-41-8 
Liquid 
C8H11ON 
137.18 
Slightly 
soluble 
Soluble 
209-211 
 
NMR 
98 % 
1.550-1.556 
1.052-1.058 
 
 
14.046 
1306 
2-Acetyl-1-
methylpyrrole 
N
O
 
3184 
11373 
932-16-1 
Liquid 
C7H9ON 
123.16 
Slightly 
soluble 
Soluble 
200-202 
 
NMR 
98 % 
1.539-1.545 
1.037-1.043 
 
 
14.047 
1307 
2-Acetylpyrrole HN
O
 
3202 
11721 
1072-83-9 
Solid 
C6H7ON 
109.13 
Soluble 
Soluble 
n.a. 
87-93 
NMR 
97 % 
n.a. 
n.a. 
 
 
14.058 
1311 
2-Isobutylpyridine N
 
3370 
11395 
6304-24-1 
Liquid 
C9H13N 
135.21 
Insoluble 
Soluble 
181 
 
NMR 
97 % 
1.480-1.486 
0.894-0.900 
 
 
14.059 
1312 
3-Isobutylpyridine N
 
3371 
11396 
14159-61-6 
Liquid 
C9H13N 
135.21 
Insoluble 
Soluble 
68-68.5 (10hPa) 
 
NMR 
97 % 
1.488-1.494 
0.898-0.904 
 
 
14.060 
1313 
2-Pentylpyridine N
 
3383 
11412 
2294-76-0 
Liquid 
C10H15N 
149.24 
Insoluble 
Soluble 
102-107 
 
NMR 
97 % 
1.485-1.491 
0.895-0.901 
 
 
14.061 
1315 
3-Ethylpyridine N
 
3394 
11386 
536-78-7 
Liquid 
C7H9N 
107.16 
Slightly 
soluble 
Soluble 
166 
 
NMR 
98 % 
1.499-1.505 
0.951-0.957 
 
 
14.065 
1317 
2,6-Dimethylpyridine N
 
3540 
11381 
108-48-5 
Liquid 
C7H9N 
107.16 
Soluble 
Soluble 
143-145 
 
MS 
1.495-1.501 
0.917-0.923 
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Table 1:  Summary of Specification Data (JECFA, 2005a) 
FL-no 
JECFA
-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index (d) 
Spec.gravity (e) 
EFSA comments 
99 % 
14.066 
1318 
5-Ethyl-2-
methylpyridine 
N
 
3546 
11385 
104-90-5 
Liquid 
C8H11N 
121.18 
Slightly 
soluble 
Soluble 
172-175 
 
NMR 
97 % 
1.495-1.502 
0.917-0.923 
 
 
14.068 
1319 
2-Propionylpyrrole HN
O
 
3614 
11942 
1073-26-3 
Solid 
C7H9ON 
123.16 
Slightly 
soluble 
Soluble 
n.a. 
43-45 
IR NMR 
99 % 
n.a. 
n.a. 
 
 
14.071 
1320 
Methyl nicotinate N
O
O
 
3709 
 
93-60-7 
Solid 
C7H7O2N 
137.14 
Slightly 
soluble 
Soluble 
n.a. 
38-43 
IR NMR MS 
98 % 
n.a. 
n.a. 
 
 
14.072 
1321 
2-(3-
Phenylpropyl)pyridin
e 
N
 
3751 
 
2110-18-1 
Liquid 
C14H15N 
197.28 
Insoluble 
Soluble 
142-143 (1 hPa) 
 
IR NMR 
97 % 
1.558-1.563 
1.012-1.018 
 
 
14.164 
1322 
2-Propylpyridine N
 
 
 
622-39-9 
Liquid 
C8H11N 
121.20 
Slightly 
soluble 
Soluble 
169-171 
 
NMR 
98 % 
1.490-1.496 
0.907-0.917 
 
 
(a): Solubility in water, if not otherwise stated. 
(b): Solubility in 95 % ethanol, if not otherwise stated. 
(c): At 1013.25 hPa, if not otherwise stated. 
(d): At 20°C, if not otherwise stated. 
(e): At 25°C, if not otherwise stated. 
n.a. not applicable. 
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4. Genotoxicity Data 
4.1. Genotoxicity Studies – Text Taken9 from JECFA (JECFA, 2006a) 
In vitro 
There was no evidence of mutagenicity in the assay for reverse mutation in bacteria when various 
strains of Salmonella typhimurium (TA97, TA98, TA100, TA102, TA104, TA1535, TA1537, TA1538 
and TM677) were incubated with indole [FL-no: 14.007] at a concentration of up to 30 µmol/plate 
(3515 µg/plate) (Anderson and Styles, 1978; Kaden et al., 1979; Florin et al., 1980; Ochiai et al., 
1986; Vance et al., 1986; Sasagawa and Matsushima, 1991; Fujita et al., 1994), isoquinoline [FL-no: 
14.001] at a concentration of up to 20,000 µg/ml (Sugimura et al., 1976; Nagao et al., 1977; Epler et 
al., 1979; Kaden et al., 1979; Sideropoulos and Specht, 1984), skatole [FL-no: 14.004] (4-
methylindole) at a concentration of up to 3 µmol/plate (394 µg/plate) (Florin et al., 1980; Ochiai et al., 
1986; Kim et al., 1989; Sasagawa and Matsushima, 1991), pyrrole [FL-no: 14.041] at a concentration 
of up to 1.4 mmol/plate (93,926 µg/plate) (Florin et al., 1980; Aeschbacher et al., 1989; Lee et al., 
1994), and 3-ethylpyridine [FL-no: 14.061] at a concentration of up to 3 µmol/plate (321 µg/plate) 
(Florin et al., 1980) with and without metabolic activation. Methyl 2-pyrrolyl ketone [FL-no: 14.047] 
(2-acetylpyrrole) at concentrations of 4 to 100 µmol/plate induced a > 2-fold increase in the number of 
revertants/plate compared with the control when tested in S. typhimurium TA98 in the absence of 
metabolic activation (Lee et al., 1994). However, negative results were obtained with metabolic 
activation as well as in S. typhimurium TA100 (both with and without metabolic activation). 
Furthermore, no mutagenic activity was reported in either strain when incubated with methyl 2-
pyrrolyl ketone at a concentration of up to 200 µg/plate with and without metabolic activation (Wang 
et al., 1994). 6-Methylquinoline [FL-no: 14.042] at a concentration of 3.3 to 3600 µg/plate gave 
uniformly positive results in the presence of metabolic activation (Sugimura et al., 1976; Nagao et al., 
1977; Dong et al., 1978; Wild et al., 1983; Takahashi et al., 1988; Debnath et al., 1992; Zeiger et al., 
1992). Methylquinolines, tested at a concentration of 400 µg/plate, showed a potent bactericidal or 
bacteriostatic effect, with only 6 % survival of S. typhimurium TA100 treated with 6-methylquinoline 
(Dong et al., 1978). 
There was no evidence of mutagenicity when Escherichia coli (strains WP2 uvr4A/pKM101, SD-4-73, 
or B/r HCR+) were incubated with indole [FL-no: 14.007] at a concentration of up to 0.4 µmol/plate 
(47 µg/plate) (Sasagawa and Matsushima, 1991), isoquinoline [FL-no: 14.001] at a concentration of up 
to 50 µg/ml, skatole [FL-no: 14.004] (3-methylindole) at a concentration of up to 0.4 µmol/plate (52 
µg/plate) (Szybalski, 1958; Sasagawa and Matsushima, 1991), or 3-acetylpyridine [FL-no: 14.039] at a 
concentration of up to 10,000 mg/plate (Pai et al., 1978). 
In non-standardised assays, 2-acetylpyridine [FL-no: 14.038] at 0.50 to 0.87 % (54000 to 93960 
µg/ml) and 3-acetylpyridine [FL-no: 14.039] at 0.5 to 1.11 % (55100 to 122322 µg/ml) caused a dose-
dependent increase in mitotic aneuploidy in strain D61.M of Saccharomyces ceverisiae (Zimmermann 
et al., 1986). At the higher test concentrations, the growth of D61.M was strongly or completely 
inhibited. The authors noted that it is generally recognised that there is a threshold dose for induction 
of aneuploidy in yeast (Zimmermann et al., 1985a; Zimmermann et al., 1985b; Zimmermann et al., 
1985c). 
Assays in mammalian cell lines have been performed for isoquinoline [FL-no: 14.001] (Williams, 
1984), skatole [FL-no: 14.004] (3-methylindole) (Kim et al., 1989), and pyrrole [FL-no: 14.041] 
(Williams, 1984). There was no evidence of increased unscheduled DNA synthesis when freshly 
isolated rat liver cells were incubated with pyrrole or isoquinoline (concentrations not specified) 
(Williams, 1984). Single-strand DNA breaks and inhibition of growth were reported when 
undeuterated or deuterated (at C2 or C3 positions) 3-methylindole (skatole) at 10 µmol/l to 1 mmol/l 
(1.31 to 131.18 µg/ml) was incubated with isolated cultured bovine kidney cells. However, there was 
                                                     
9
  The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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no evidence of DNA interstrand crosslinks (Kim et al., 1989). These observations are consistent with 
reports that, at high concentrations, indoles deplete glutathione, leading to increased formation of 
DNA adducts (Nichols et al., 2000; Regal et al., 2001). 
In vivo 
There was no evidence for mutation in a standard assay for sex-linked recessive lethal mutation when 
adult Drosophila melanogaster were fed 6-methylquinoline [FL-no: 14.042] at a concentration of 
10 mmol/l (1432 µg/ml) in a 5 % sucrose solution for 3 days (Wild et al., 1983). Furthermore,  
6-methylquinoline did not induce micronucleus formation in bone marrow cells obtained from male 
and female NMRI mice 30 hours after treatment with the test compound as a single intraperitoneal 
dose at 0, 286, 429, or 572 mg/kg bw (Wild et al., 1983). 
Conclusion on genotoxicity 
Overall, negative results were reported in assays for reverse mutation in bacteria for six representative 
pyridine, pyrrole and quinoline derivatives (i.e. indole [FL-no: 14.007], isoquinoline [FL-no: 14.001], 
skatole [FL-no: 14.004] (3-methylindole), methyl 2-pyrrolyl ketone [FL-no: 14.047] (2-acetylpyrrole), 
pyrrole [FL-no: 14.041] and 3-ethylpyridine [FL-no: 14.061]). Although 6-methylquinoline gave 
positive results with metabolic activation, it gave negative results in studies in vivo, indicating that 
there are adequate detoxication mechanisms for the rapid absorption, distribution, biotransformation 
and elimination of the N-containing heteroaromatic derivatives. 2-Acetylpyridine and 3-acetylpyridine 
produced positive results in yeast, but this is unlikely to occur at low doses because yeast is generally 
believed to have a threshold for the induction of aneuploidy. The positive results reported in bacteria 
for skatole (3-methylindole) are consistent with observations that, at high concentrations, indoles 
deplete glutathione, leading to reduced detoxification. 
On the basis of the available evidence, the 22 pyridine, pyrrole and quinoline derivatives in this group 
do not demonstrate genotoxic potential. 
For a summary of in vitro/in vivo genotoxicity data considered by JECFA, see Table 2. 
4.2. Genotoxicity Studies – Text Taken10 from EFSA FGE.24Rev2 (EFSA CEF Panel, 2013) 
In vitro / in vivo 
Genotoxicity data were provided for seven of the 24 candidate substances. In in vitro studies on the 
candidate substances 2-methylindole [FL-no: 14.131], 2-methylpyridine [FL-no: 14.134], 3-
methylpyridine [FL-no: 14.135], 4-methylpyridine [FL-no: 14.136], 2,4-dimethylpyridine [FL-no: 
14.104], 3,5-dimethylpyridine [FL-no: 14.106] and 4-acetylpyridine [FL-no: 14.089] in doses up to 
10000 µg/plate, with and without metabolic activation, did not cause reverse mutations in various 
strains of S. typhimurium (Table 3 in present FGE.77Rev2). 
Studies on induction of aneuploidy in S. cerevisiae D61.M available for the three candidate substances 
2-methylpyridine [FL-no: 14.134], 2,4-dimethylpyridine [FL-no: 14.104] and 4-acetylpyridine [FL-no: 
14.089] gave positive results. The positive results were obtained at high doses inhibiting the growth of 
the yeast. Furthermore, fungal systems for measuring aneuploidy have little relevance compared to the 
mammalian system. 
No in vivo studies on genotoxicity of the candidate substances were available. 
Genotoxicity tests are available for the eight supporting substances [FL-no: 14.004, 14.007, 14.038, 
14.039, 14.041, 14.047, 14.061 and 14.065]. 2-Acetylpyrrole [FL-no: 14.047] (methyl 2-pyrrolyl 
                                                     
10
 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
 FGE has been removed. 
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ketone) was positive in TA98 without metabolic activation at the two highest concentrations tested. 
Negative results were obtained at the lowest concentration as well as with metabolic activation. This 
study is considered of limited relevance. Pyrrole [FL-no: 14.041], indole [FL-no: 14.007], 3-
methylindole [FL-no: 14.004] (skatole), 3-ethylpyridine [FL-no: 14.061] and 2-acetylpyridine [FL-no: 
14.038] were negative in bacterial mutation assays. 
Studies on induction of aneuploidy in S. cerevisiae D61.M are available on three supporting 
substances, 2,6-dimethylpyridine [FL-no: 14.065], 2-acetylpyridine [FL-no: 14.038] and 3-
acetylpyridine [FL-no: 14.039], which gave positive results. However, as for the three candidate 
substances, the positive results were obtained at high doses inhibiting the growth of the yeast. 
Furthermore, fungal systems for measuring aneuploidy have little relevance compared to the 
mammalian system. 
In vivo data are available for one supporting substance. 
3-Methylindole (skatole) [FL-no: 14.004] was reported negative in the micronucleus assay in mice. 
The validity of this study, however, cannot be evaluated, as only an abstract is available.  
Positive results were obtained for some candidate and supporting substances in the Rec, DNA 
breaking, CHO and DNA synthesis assays. These results are, however, not considered valid. 
Conclusion on genotoxicity 
The genotoxicity data available for the candidate substances do not preclude their evaluation through 
the Procedure. 
For a summary of in vitro / in vivo genotoxicity data considered by EFSA, see Tables 3 and 4. 
4.3. Genotoxicity Studies Evaluated by the Panel in FGE.77Rev1 
6-Methylquinoline [FL-no: 14.042] 
6-Methylquinoline [FL-no: 14.042] was found to induce chromosome aberrations and sister chromatid 
exchanges (SCE) in Chinese hamster ovary (CHO) cells (NTP, 1986). 
A micronucleus assay was performed by Nakajima (2005) essentially in line with the OECD Guideline 
474. No significant increase of micronucleated polychromatic erythrocyte (PCE) frequency was 
observed in any groups of BDF1 male mice, treated by gavage at 225, 450 and 900 mg/kg body weight 
(bw) for two subsequent days, 24 hours apart. No significant decrease in the percentage of 
polychromatic erythrocytes to the analysed total erythrocytes (% PCE) was observed in any treatment 
group (Nakajima, 2005). The lack of cytotoxicity in the bone marrow cells does not allow a conclusion 
as whether the test substance or a reactive metabolite (e.g., an electrophilic epoxide) reached the bone 
marrow. Therefore, the results of this study have to be considered of limited relevance. 
A bone marrow micronucleus assay was performed by Honarvar (2004) on a structurally related 
substance, 6-isopropylquinoline, which was in compliance with GLP and OECD Guideline 474. No 
significant increase of micronucleated PCE frequency was observed in any group of NMRI mice 
orally treated with 6-methylquinoline at 500, 1000 and 2000 mg/kg bw at 24 hours after treatment and 
for the highest dose, 2000 mg/ kg bw also 48 hours after treatment (Honarvar, 2004). Slight cytotoxic 
effects in the bone marrow (less than 10 % changes in PCE/NCE ratio) were observed, only at the high 
dose. Also at the high dose group 48 hours after treatment the percentage of micronucleated cells 
(0.118) was higher than the corresponding vehicle control (0.065). The value was within the historical 
control range (up to 0.15 %). Also in this case, due to the limited cytotoxicity, it is not clear whether 
the test substance/metabolite reached the target (bone marrow) in sufficient concentrations to elicit 
genotoxic effects. 
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For a summary of in vitro / in vivo genotoxicity data on 6-methylquinoline, see Tables 5 and 6. 
4.4. EFSA Considerations  
The Panel concluded that one of the 22 substances evaluated by JECFA, 6-methylquinoline [FL-no: 
14.042], showed a genotoxic potential in vitro, with consistently positive results in several bacterial 
mutagenicity tests after metabolic activation. 6-Methylquinoline was reported negative in a test for 
gene mutations in Drosophila and in a micronucleus test in mice; however, the latter study did not 
meet current guidelines (PCE/NCE ratio not reported). The new genotoxicity studies submitted on 6-
methylquinoline showed negative results in the micronucleus assay by Nakajima (2005), which was 
considered of limited relevance due to the lack of cytotoxicity in the bone marrow, which would have 
been indicative for target exposure. Similarly, the results of the micronucleus assay by Honarvar 
(2004) on the structurally related substance 6-isopropylquinoline, were considered of limited relevance 
due to the lack of evidence of target tissue exposure. The negative results of these two studies are not 
sufficient to overrule the concern on the genotoxic potential of 6-methylquinoline, which was 
observed in vitro, induction of gene mutations in bacterial cells, chromosome aberrations and sister 
chromatid exchanges (SCE) in cultured mammalian cells after metabolic activation (S9). Therefore, in 
line with the requirements in the EFSA guidance document (EFSA Scientific Committee, 2012) 
further in vivo testing is recommended with a more appropriate and sensitive assay, i.e. a Comet assay 
with liver as target organ to alleviate the concern for genotoxicity of 6-methylquinoline. Accordingly, 
the Panel concluded that 6-methylquinoline [FL-no: 14.042] could not be evaluated through the 
Procedure. For the remaining 21 JECFA evaluated pyridine, pyrrole and quinoline derivatives, the data 
available do not preclude evaluation through the Procedure. 
5. New Toxicity Data 
Additional toxicity data have since the publication of FGE.77 (EFSA, 2009) been provided for 
isoquinoline [FL-no: 14.001], pyrrole [FL-no: 14.041] and 2-acetylpyrrole [FL-no: 14.047], the latter 
also to cover the evaluation of the structurally related 2-propionylpyrrole [FL-no: 14.068]. The main 
studies provided are for each substance a 90-day study. Since the publication of FGE.77Rev1 (EFSA. 
2014), additional toxicity data have been provided for 1-furfurylpyrrole [FL-no: 13.134]. The data are 
intended to cover the re-evaluation of this substance and 2-acetyl-1-ethylpyrrole [FL-no: 14.045] and 
2-acetyl-1-methylpyrrole [FL-no: 14.046]. The main study provided is a 90-day study. 
5.1. Isoquinoline [FL-no: 14.001] 
A 90-day oral study in rats was performed according to the Japanese “Guidelines for designation of 
food additives and revision of standards for use of food additives, Notification No 29” of the 
Environmental Health Bureau, Ministry of Health and Welfare, Japan, March 22, 1996. The 
requirements of this guideline are very similar to the OECD Guideline 408. It is a GLP study. Groups 
(10/sex/dose) of male and female Sprague-Dawley rats were administered 0 (vehicle control), 0.03, 
0.3 and 3 mg/kg bw/day of isoquinoline dissolved in corn oil by gavage daily for 90 and 91 days for 
males and females, respectively (Kojima, 2006). The purity of the test article was 98.5 %. Animals 
were weighed at the start of the study and weekly thereafter. Food consumption and efficiency were 
measured weekly. The rats were caged individually during the experiment. All animals were subject to 
ophthalmologic examination prior to the start of the study and on day 79, five animals of each sex per 
group were examined again. Urine was analysed on day 82 for five animals from each group. The rats 
were fasted for 18 - 21 hours prior to blood sampling immediately prior to necropsy. A full 
haematological and biochemical analysis of blood was performed. At termination of the study, animals 
were sacrificed and subject to full necropsy. Histopathological examination was performed on all 
organs (as in the OECD Guideline 408) for the control and high dose group.  
No animals died through the course of the study. No clinical signs of toxicity or behavioural changes 
were observed. Ophthalmological examination revealed no treatment related changes. Mean body 
weights were comparable throughout the study between control and test groups of both sexes. Urine 
analysis did not reveal any treatment-related alterations when compared to controls. Haematology and 
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blood chemistry results showed no significant differences between the test groups and controls. There 
were no organ weight changes or other macroscopic findings attributable to the administration of the 
test substance. 
Histopathological examination did not show differences between controls and treated animals of either 
sex; some incidental findings occurred in both controls and treated animals, but there was no 
significant difference in their occurrence or intensity in the various organs when compared to the 
control groups. 
Since there were no statistically significant changes due to the administration of the test material, the 
NOAEL of isoquinoline was determined to be 3 mg/kg bw/day in male and female rats after 90 days 
of administration by oral gavage (Kojima, 2006). 
5.2. Pyrrole [FL-no: 14.041] 
In a gavage study (Marumo, 2008), groups (10/dose/sex) of male and female Sprague-Dawley rats 
were administered 0 (vehicle control), 0.03, 0.30 and 3.00 mg/kg bw of aqueous pyrrole daily, by 
gavage for 90 days prior to necropsy. This study was performed according to “Guidelines for 
designation of food additives and for revision of standards for use of food additives”, Notification No 
29 of the Environmental Health Bureau, Ministry of Health and Welfare, Japan, March 22, 1996 
which is comparable to an OECD Guideline 408 study. It is a GLP study. Clinical observations were 
recorded daily and body weights and food consumption were recorded weekly. On Day 79, five 
animals from each group were subject to ophthalmology examination. Urine samples were collected 
on day 82 for routine clinical chemical analysis. At termination, blood samples were taken for clinical 
chemistry determinations and haematological examination. At necropsy, organ weights for all organs 
required for an OECD Guideline 408 study were recorded. Tissues from all organs required in an 
OECD Guideline 408 study from both sexes of the control and 3.00 mg/kg bw/day groups were fixed 
and preserved for histopathological examination. 
No mortality was observed throughout the course of the study and the general condition of the rats was 
unremarkable. Mean body weight gains and food consumption were comparable across test and 
control groups. Ophthalmologic examination revealed that in some animals in all male groups, 
controls included, and some females of the 0.03 and 3.00 mg/kg bw/day groups corneal clouding was 
observed.  
Urine analysis revealed no toxicologically significant findings except that one male rat out of five in 
the 3.00 mg/kg bw/day group showed some changes, suggesting a possible kidney effect at that level; 
however, there were no indications of kidney pathology in the histopathological findings of this rat. In 
the females there were no effects observed in urinalysis except that they showed significantly higher 
concentrations of sodium, potassium and chloride ions, but this was not dose dependent. Males and 
females in the 3.00 mg/kg bw/day groups showed an increase in “urobilinogen concentrations” in 
blood, but this was not accompanied by associated histopathology in the liver, spleen, bone marrow or 
haemolysis; the effect can be attributed to the interference of pyrrole present in urine in the 
colorimetric assay; it gives the same reaction as urobilinogen in the detection method used. 
In female rats the white blood cell count was lower for all three exposure levels than the control group, 
but this showed no dose-relationship; the values were 4600 ± 1500, 3600 ± 900, 3400 ± 800 and 3400 
± 1100 per µL, respectively. At the two higher dose levels, this was statistically significant (P < 0.05). 
None of the other haematological parameters was changed as compared to controls. In male rats there 
was no difference in white blood cell levels or any other haematological parameter. Small changes in 
blood biochemical findings in male rats at the highest exposure were considered incidental. 
Gross pathology examination revealed some organ weight variations including decreased absolute and 
relative pituitary gland weights only in low dose treated male rats. All groups of male rats showed a 
somewhat decreased relative seminal vesicle weight due to a combination of increased body weight in 
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the treated rats in combination with a slight decrease in absolute seminal vesicle weight. However, 
histopathology did not reveal abnormalities, neither in pituitary gland nor in seminal vesicles. 
Histopathological examination was performed on all high dose and control animals, along with any 
tissues with lesions at other doses. In the lungs, alveolar accumulation of foamy cells was observed in 
eight males and three females at the 3.00 mg/kg bw dose and in four male controls. Mineralisation of 
the pulmonary arterial wall was reported for five males and two females of the high-dose group and 
two male controls. Focal thickening of alveolar septum with neutrophilic infiltration was seen in two 
high dose male rats. Basophilic tubules were noted in the kidney cortex of eight males and five 
females of the high dose group and five females of the control group. Atrophy of the seminiferous 
tubule was observed in two male in the high dosed group but the changes were very slight. In female 
in the high dosed group, single animals showed follicle cysts or retention of the corpus luteum with a 
marked decrease of eosinophils in the endometrium and myometrium or marked mucification of the 
vaginal mucosa. Most of these phenomena were observed in both the treated and the control groups 
and they are therefore considered incidental findings. 
The lower white blood cell count in the females is considered an incidental finding and not considered 
an adverse effect since the count of all other blood cells types were normal in the female treated 
groups. In the males no lower blood count for any cell types was observed, the histopathological 
examination revealed no correlating changes in the haematopoietic tissue and there was no dose-effect 
relationship (raising the question whether the control value was incidentally too high; the company, 
unfortunately, did not give an indication of historical control values in their report). The Panel 
decided, based on the findings, that the NOAEL level was the highest exposure level 3.0 mg/kg 
bw/day. 
5.3. 2-Acetylpyrrole [FL-no: 14.047] 
5.3.1. A 14-Day Range Finding Study 
In a 14-day range-finding dietary study (Bauter, 2012a), groups (3/sex/dietary intake level) of male 
and female Sprague Dawley rats were fed a diet designed to provide 0 (dietary control), 1000, 9000 
and 18000 mg/kg feed of 2-acetylpyrrole [FL-no: 14.047] daily. These estimated dietary levels 
correspond to the measured intake of 0, 85, 550 and 842 mg/kg bw/day for males and 0, 91, 582 and 
949 mg/kg bw/day for females, respectively. Clinical observations were recorded daily and body 
weights were recorded on days 0, 7, 11 and 12. Individual food consumption was recorded on days 7 
and 12. Due to increasing mortality in the high intake groups of both sexes, the study was terminated 
early at day 12. The results showed that the two higher doses were too toxic for a 90 day study. A 
90 day study was started at lower exposure levels. 
5.3.2. Effect on Urinary Iron and Copper Excretion 
The company also studied the effect of 2-acetylpyrrole [FL-no: 14.047] on urinary excretion of iron 
because 2-acetylpyrrole is a strong complexing agent of metal ions. At a very high dose gavage study 
in rats (375 mg/kg bw orally for 10 days), the urinary excretion of total iron was increased 6-fold 
(Mendes, 2012); no data are provided on absorption of iron from the intestinal tract, which might be 
influenced by complexation of iron with 2-acetylpyrrole. 
5.3.3. 90-Day Study 
In an OECD (408) compliant 90-day study, groups of rats (10/sex/dietary intake level) of male and 
female Sprague-Dawley CD rats were fed a diet designed to provide 0 (dietary control), 1050, 2100 
and 4200 mg 2-acetylpyrrole [FL-no: 14.047]/kg feed daily (Bauter, 2012b). These dietary levels 
correspond to the calculated average daily intakes of 0, 68, 133 and 263 mg/kg bw for males and 0, 79, 
155 and 298 mg/kg bw for females, respectively. 
The test material was not stable in the diet, and in the report (Bauter, 2012b) it is suggested that part of 
it was probably not detected by the extraction method employed due to complexation with metal ions 
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in the feed. It is calculated that over the course of the study the animals received concentrations of 35 - 
40 % of the target intake level on average. Therefore, values for exposure levels based on the 
measured intake are proportionally lower. Based on this analysis of the test diets, the mean daily 
intakes were calculated to are 367, 754 and 1705 mg/kg feed. Assuming that the toxicity is only 
related to the free 2-acetylpyrrole, these dietary concentrations correspond to average daily intakes of 
24, 48 and 107 mg/kg bw for males and 28, 56 and 121 mg/kg bw for females, respectively, over 
90 days. 
Clinical observations of toxicity were performed on day 0 and weekly until sacrifice. Animals were 
weighed on day 0 at the start of the study and weekly thereafter. Food consumption and efficiency 
were measured and calculated weekly. Blood chemistry and haematology were performed on blood 
drawn via sublingual bleed at day 43 for the controls and high intake groups and at day 86 for all 
groups after overnight fast. Urine was collected during the 15 hours prior to the blood draw. Prior to 
initiation of the study and on day 91, the eyes of all rats were examined by focal illumination and 
indirect ophthalmoscopy. At termination of the study all survivors were sacrificed and subject to full 
necropsy and histopathology as required by the OECD Guideline. 
There were no mortalities or ophthalmological changes associated with the presence of 2-acetylpyrrole 
in the diet. Most other findings, generally also noted in control animals, were not considered adverse 
effects of test substance administration and were regarded as incidental. Statistically significant 
concentration-dependent reductions in body weight, body weight gain, food consumption (males and 
females) and food efficiency (females) at the highest dietary level (1705 mg/kg feed measured 
concentration) during the study were attributed to the possible decrease in test substance palatability at 
high dietary levels. 
Haematology parameters for both males and females were mostly unchanged during treatment. 
Although incidentally reaching a statistically significant difference when compared to concurrent 
controls, the values were in general within the range of historical controls and without associated 
histopathology correlate; they were therefore considered to be incidental and not related to the test 
material. However, statistically significantly (p < 0.05) decreased total white blood cell counts, 
erythrocyte counts, haemoglobin concentrations, haematocrit, absolute lymphocyte counts, absolute 
monocyte counts and absolute basophil counts and increased red cell distribution width were reported 
in the high intake group females on day 86. These parameters are outside of historical control levels 
although the variations are low in magnitude. There were no meaningful differences in coagulation 
parameters between test and control groups of both sexes. 
Variations in clinical chemistry parameters were considered incidental and unrelated to the presence of 
2-acetylpyrrole in the diet due to lack of concentration-dependence or correlated pathology. 
Organ weight measurements, absolute and relative brain weight, for males were comparable to 
controls, with some isolated exceptions; these were without histologic correlate and were considered 
unrelated to test substance in the diet. 
Female rats of the high intake groups displayed minimal to moderate dark bilateral thyroid glands. 
Microscopic changes were slight thyroid hypertrophy/hyperplasia among 4/10 and 10/10 high intake 
group males and females, respectively. This was characterised by enlarged subgross tall columnar 
appearance of the follicular epithelial cells which appeared with fine cytoplasmic vacuolation with 
intermittent focally piled papillary projections into the follicular lumen. The company did not provide 
a clear (mechanistic) explanation for this finding. 
In conclusion, although some haematology and clinical parameter changes were observed in mid and 
high dose groups, in the mid dose were considered incidental and not of concern (not dose-related 
and/or very small in magnitude and/or within historic controls and without histopathology correlation). 
However, the thyroid effects at the exposure level are of concern, as well as the haematological 
changes in the high dose females. Therefore, a NOAEL for 2-acetylpyrrole is derived from the middle 
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dose 48 mg/kg bw/day in males and 56 mg/kg bw/day in females. The NOAEL value of 48 mg/kg 
bw/day is used in calculating the margin of safety. 
5.3.4. Metabolites of 2-Acetylpyrrole 
Mendes (Mendes, 2012) analysed the urine obtained in metabolism cages from rats dosed with 2-
acetylpyrrole [FL-no: 14.047] at 375 mg/kg by oral gavage as described in 5.3.2. Based on GC-MS 
analysis, three major components were identified in the urine of both males and females treated with 
2-acetylpyrrole. Unchanged 2-acetylpyrrole and pyrrol-2,5-dione were detected; the structure of 
another main metabolite detected in the urine is proposed to be 1,5-dihydropyrrol-2-one, however, 
further experiments have yet to be performed to confirm this. 
5.4. 1-furfurylpyrrole [FL-no: 13.134] 
5.4.1. A 14-Day Range Finding Study 
In a 14-day palatability and range-finding dietary study (Kappeler, 2013a) 1-furfurylpyrrole [FL-no: 
13.134] was administered to male and female Crl:CD(SD) rats (3/sex/group) for 14 consecutive days 
in the diet to provide 0, 25, 75 and 200 mg/kg bw/day (Kappeler, 2013a). Observations for mortality 
and morbidity were performed twice daily and clinical examinations were performed once daily. 
Detailed physical examinations including body weight measurements were performed within 4 days of 
receipt, on the day of randomization, prior to dosing on study day 0 (body weights, only) and weekly 
during the study. Food consumption was recorded one week prior to randomization, on the day of 
randomization, and weekly throughout the study. Based on food consumption measurements, the 
calculated doses of 1-furfurylpyrrole were 0, 29, 84 and 211 mg/kg bw/day, respectively, for males 
and 0, 27, 81 and 192 mg/kg bw/day, respectively, for females over the entire study. All animals 
survived the 14 days of diet administration. 
There were no overt adverse effects from 1-furfurylpyrrole administration. The only differences from 
control group animals were body weight reductions of 18 % and 16 % for males and females, 
respectively, in the 200 mg/kg bw/day group, that were associated with lower food consumption 
levels. It was concluded that 1-furfurylpyrrole was well tolerated in Crl:CD(SD) rats at dietary levels 
of up to 84 mg/kg bw/day and 81 mg/kg bw/day for males and females, respectively. 
5.4.2. 90-Day Study 
In an OECD test guideline 408 compliant 90 day dietary study (GLP), 1-furfurylpyrrole [FL-
no:13.134] (purity 99,6 %) was administered to individually housed Crl:CD(SD) rats (10/sex/group) at 
levels calculated to provide nominal doses of 0, 25, 75, and 150 mg/kg bw/day (Kappeler, 2013b). All 
animals were subject to observations for mortality and morbidity twice daily, daily clinical 
examinations and weekly detailed physical examinations, including body weight and food 
consumption measurements. Ophthalmic examinations were performed before the start of the study 
and in week 12. Clinical pathology parameters (haematology, coagulation, serum chemistry, and 
urinalysis) were evaluated for all animals at the scheduled necropsy, after 13 weeks of treatment. 
Blood for haematology and serum chemistry was collected at necropsy after overnight fast and urine 
was collected overnight prior to necropsy. Coagulation was measured in blood collected from 
anesthetized animals prior to sacrifice. All tissues were examined microscopically for animals of the 
150 mg/kg bw/day groups. In addition, liver, spleen and nasal tissues were also examined for animals 
of the two lower intake level groups.  
Based on food consumption data, the mean intake of 1-furfurylpyrrole was calculated to be 25, 77 and 
154 mg/kg bw/day for males and 25, 75 and 151 mg/kg bw/day for females. All animals survived to 
the end of the study. There were no differences between treated and control groups noted in clinical 
observations, macroscopic findings or urinalysis, except for an increase in urobilinogen concentration.  
By the time of necropsy body weights were lower in the 150 mg/kg bw/day dose group for both males 
(−17 %) and females (−11 %) and in the 75 mg/kg bw/day dose group of females (−8 %), relative to 
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the control group. Decreased food consumption was also observed. These decreases were statistically 
significant for the male group at 150 mg/kg bw/day beginning on the first week and throughout the 
length of the study; for the female groups the decrease was not statistically significant, although the 
weight gain in these females was decreased statistically significantly. Slightly lower body weights 
were noted in the 25 and 75 mg/kg bw/day males and the 25 mg/kg bw/day females (4 %, 5 % and 
6 %, respectively). 
Reductions in red blood cell counts (0.6 %, 7.0∗ % and 9.3∗∗ %), haemoglobin levels (3.6 %, 5.4* % 
and 9.6** %), and haematocrit values (3.7 %, 7.2* % and 9.9** %) and slightly higher red blood cell 
distribution widths (4.1 %, 4.9** % and 4.1** %) were observed in all treated groups (25, 75 and 
150 mg/kg bw/day, respectively) of males, but were not observed in females. The effect at the lower 
exposure level was considered minor. Histopathology showed no changes in bone marrow at the 
highest dose level. Pigment deposits in the red pulp of the spleen were minimally increased only at the 
highest dose level in eight out of 10 males; for females this was one out of 10 at the middle dose and 
four out of 10 at the highest dose.  
In males, dose-dependent changes in serum chemistry values included higher total bilirubin 
(0.01±0.03, 0.02±0.04, 0.07±0.05** and 0.08±0.04** mg/dL respectively), which might be related to 
the reduced red blood cell counts and cholesterol (39*, 84** and 91** % respectively). In females 
similar increases were not dose-dependent: 0.04±0.05, 0.09±0.03**, 0.11±0.03** and 0.10±0.00** 
mg/dL) for total bilirubin and 41**, 33* and 66** % for cholesterol. In parallel with the higher total 
bilirubin levels, the urobilinogen concentration in urine was increased at the higher dose levels. Only 
at the highest dose sorbitol dehydrogenase (SDH) values in both sexes were increased by 111** and 
33 % in males and females respectively.  
The increases in total bilirubin and cholesterol suggest effects on the liver. Higher mean liver weights 
relative to final body weight were noted in the male (6, 16** and 32** %) and female groups (12**, 17** 
and 32** % increase based on body weight). Centrilobular hepatocellular vacuolation was observed in 
the 75 and 150 mg/kg bw/day male groups and the 150 mg/kg bw/day group females only. The male 
groups scored 5/10 minimal and 5/10 mild at the highest dose; 4/10 minimal and 1/10 mild at the 
middle dose; 0/10 at the lowest dose; against 0/10 in the controls; the females showed only at the 
highest dose in 7/10 centrilobular vacuolisation against 0/10 in the control and both lower dose groups.  
Other microscopic changes were identified in nasal sections and spleen. In the spleen, findings were 
limited to a very minimal increase in pigment deposits that were mainly restricted to the 150 mg/kg 
bw/day dose group. Microscopically, changes in nasal tissue included olfactory mucosa degeneration, 
depleted mucous secretion by goblet cells and thin deposits of a hyaline material along the surface of 
the olfactory epithelial cells. Olfactory mucosa degeneration was observed in both sexes at the 75 and 
150 mg/kg bw/day intake levels and was slightly more prevalent and severe in males. The findings in 
the olfactory mucosa were considered to be adverse. Depleted mucous secretion by goblet cells was 
especially prominent in Nasal Section I and was observed in most rats administered 1-furfurylpyrrole.  
It is concluded that exposure to 1-furfurylpyrrole [FL-no: 13.134] in the diet for 90 days resulted in 
adverse effects in the 75 and 150 mg/kg bw/day groups of males and females and consisted of effects 
on liver, red blood cells and olfactory mucosa. Therefore, the no-observed adverse-effect level 
(NOAEL) of [FL-no: 13.134] was 25 mg/kg bw/day for male and female Crl:CD(SD) rats.  
 
                                                     
∗
  Significant at 0.05 according to Dunnett’s test 
∗∗
  Significant at 0.01 according to Dunnett’s test 
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6. Application of the procedure 
6.1. Application of the Procedure to 22 Pyridine, Pyrrole and Quinoline Derivatives by 
JECFA (JECFA, 2006a) 
 
According to JECFA, three of the substances belong to structural class I, 13 to structural class II and 
six to structural class III, using the decision tree approach presented by Cramer et al. (1978). 
JECFA concluded 20 pyridine, pyrrole and quinoline derivatives at step A3 in the JECFA Procedure, 
i.e. the substances are expected to be metabolised to innocuous products (step 2) and the intakes for all 
substances are below the thresholds for their structural classes I, II and III (step A3). 
Two substances, 1-furfurylpyrrole [FL-no: 13.134] and 2-pyridine methanethiol [FL-no: 14.030], were 
evaluated via the B-side of the Procedure as the substances could not be anticipated to be metabolised 
to innocuous products. For these substances, the intake is below the threshold for the structural class 
III (step B3) and a NOAEL exists to provide an adequate margin of safety to the estimated intake as 
flavouring substances (step B4). For 1-furfurylpyrrole [FL-no: 13.134], a NOAEL of 12 mg/kg bw/day 
from a 90-day feeding study in rats (Morgareidge, 1971) is > 1,000,000 times greater than the 
estimated current intake of this substance as a flavouring substance. For 2-pyridine methanethiol [FL-
no: 14.030], the NOAEL of 3.4 mg/kg bw/day from a 90-day feeding study in rats (Posternak et al., 
1969) is > 20,000,000 times higher than the estimated current intake of this substance as a flavouring 
substance. 
In conclusion, JECFA evaluated all 22 substances as to be of no safety concern at the estimated levels 
of intake as flavouring substances based on the MSDI approach. 
The evaluations of the 22 pyridine, pyrrole and quinoline derivatives are summarised in Table 8. 
6.2. Application of the Procedure to 24 Pyridine, Pyrrole, Indole and Quinoline Derivatives 
from Chemical Group 28 evaluated by EFSA in FGE.24Rev2 (EFSA CEF Panel, 2013)  
Twenty-four candidate substances were evaluated in FGE.24Rev2. Twenty-two of the 24 candidate 
substances are classified into structural class II and two substances into structural class III using the 
decision tree approach presented by Cramer et al. (1978). 
Two of the substances, ethyl nicotinate [FL-no: 14.110] and isopropyl nicotinate [FL-no: 14.120], 
were concluded at step A3, i.e. the substances are expected to be metabolised to innocuous products 
(step 2) and the estimated daily intake is below the threshold for the structural class (step A3). 
The remaining 22 substances were concluded at step B4, i.e. the substances could not be anticipated to 
be metabolised to innocuous products (step 2) and the estimated daily intake is below the threshold for 
the structural class (step B3). For the 22 substances, NOAELs could be derived to provide adequate 
margins of safety to the estimated levels of intake as flavouring substance (step B4). 
For the candidate substance 2-acetyl-5-methylpyrrole [FL-no: 14.085], a NOAEL of 48 mg/kg bw/day 
for the supporting substance 2-acetylpyrrole [FL-no: 14.047] is derived. The estimated daily per 
capita intake of 0.0012 µg for 2-acetyl-5-methylpyrrole [FL-no: 14.085] corresponds to 0.02 ng/kg 
bw/day at a body weight of 60 kg. Thus, a margin of safety of 2.4 × 109 can be calculated. 2-Acetyl-5-
methylpyrrole is accordingly not expected to be of safety concern at the estimated level of intake. 
In an oral 37 weeks feeding study in rats on indole-3-carbinole, a substance structurally related to the 
two indole derivatives in this FGE (FGE.24Rev2), a NOAEL of 50 mg/kg bw/day could be derived. 
The combined estimated daily per capita intake of 0.0024 µg for 1-acetylindole [FL-no: 14.088] and 
2-methylindole [FL-no: 14.131] corresponds to 0.04 ng/kg bw/day at a body weight of 60 kg. Thus, a 
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margin of safety of 1.3 × 109 can be calculated. 1-Acetylindole [FL-no: 14.088] and 2-methylindole 
[FL-no: 14.131] are accordingly not expected to be of safety concern at the estimated level of intake. 
A 90 days oral feeding study in rats is available for the supporting substance 2-acetylpyridine [FL-no: 
14.038]. The NOAEL derived is 37 mg/kg bw/day. The MSDI values for the 19 pyridine derivatives in 
this FGE (EFSA CEF Panel, 2013) are between 0.012 and 0.21 µg/capita/day. The combined 
estimated daily per capita intake of these 19 derivatives is 1.5 µg, corresponding to 0.025 µg/kg 
bw/day. Thus, a margin of safety of 1.5 × 106 can be calculated using the NOAEL of 37 mg/kg 
bw/day. The 19 pyridine derivatives in this flavouring group are accordingly not expected to be of 
safety concern at the estimated level of intake. 
In conclusion, the Panel evaluated the 24 substances as to be of no safety concern at the estimated 
levels of intake as flavouring substances based on the MSDI approach. 
The stepwise evaluations of the 24 substances are summarised in Table 9. 
6.3. EFSA Considerations 
The Panel agrees with the way the application of the Procedure has been applied by JECFA for four of 
the 22 substances. Methyl nicotinate [FL-no: 14.071], indole [FL-no: 14.007] and 3-methylindole [FL-
no: 14.004] were evaluated via the A-side of the Procedure as they were anticipated to be metabolised 
to innocuous products. For these three substances, EFSA agreed no safety concern at step A3 of the 
Procedure, as the intake is below the threshold of the structural class (Cramer et al., 1978). 1-
Furfurylpyrrole [FL-no: 13.134] and 2-pyridine methanethiol [FL-no: 14.030] were the only two 
substances evaluated through the B-side of the Procedure as the substances were not anticipated to be 
metabolised to innocuous products by JECFA. For 1-furfurylpyrrole [FL-no: 13.134]11, EFSA 
disagreed with JECFA, as the 90-day feeding study in rats (Morgareidge, 1971) was considered a 
poorly reported old study, the quality of which cannot be assessed, as stated in FGE.24Rev2 (EFSA 
CEF Panel, 2013). For 2-pyridine methanethiol [FL-no: 14.030], EFSA agrees with JECFA. 
For 6-methylquinoline [FL-no: 14.042], contrary to JECFA, the Panel concluded in FGE.77, that this 
substance should not be evaluated using the Procedure until adequate in vivo genotoxicity data become 
available. Additional genotoxicity data have after the publication of FGE.77 become available for 6-
methylquinoline, which have been evaluated in Revision 1 of FGE.77, however, the data are not 
sufficient to overrule the concern on the genotoxic potential of 6-methylquinoline. Therefore the Panel 
reiterated concern on the genotoxic potential of 6-methylquinoline and concluded that this substance 
should not be evaluated using the Procedure until adequate genotoxicity data become available. 
For the remaining 16 substances the Panel, in contrast to JECFA, did not anticipate that they will be 
metabolised to innocuous products due to concern with respect to N-oxidation of pyridines and for the 
pyrroles concerns about N-oxidation and epoxidation and accordingly concluded that they should be 
evaluated along the B-side. However, in FGE.77, for 10 [FL-no: 14.038, 14.039, 14.058, 14.059, 
14.060, 14.061, 14.065, 14.066, 14.072 and 14.164] of these 16 substance, a NOAEL could be derived 
to provide adequate margins of safety to the estimated level of intakes as flavouring substance (step 
B4). A 90-day oral feeding study in rats is available for 2-acetylpyridine [FL-no: 14.039]. The 
NOAEL derived is 37 mg/kg bw/day (Til and van der Meulen, 1971). The MSDI values for the 10 
pyridine derivatives in this FGE are between 0.06 and 50 µg/capita/day. The combined estimated daily 
per capita intake of the 10 pyridine derivatives evaluated through the B-side is 57 µg corresponding to 
0.95 µg/kg bw/day. Thus, a margin of safety of approximately 39000 can be calculated using the 
NOAEL of 37 mg/kg bw/day. The 10 pyridine derivatives in this flavouring group evaluated through 
the B-side are accordingly not expected to be of safety concern at the estimated levels of intake. 
For pyrrole [FL-no: 14.041] and the five pyrrole derivatives [FL-no: 13.134, 14.045, 14.046, 14.047 
and 14.068] as well as for isoquinoline [FL-no: 14.001], NOAELs could not be derived as such or for 
                                                     
11
 [FL-no: 13.134] has been removed from FGE.24 Revision 2 
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structurally related substances in FGE.77. Accordingly, additional toxicological data were required for 
these seven substances (step B4) in FGE.77. 
Additional toxicity data have after the publication of FGE.77 become available for isoquinoline [FL-
no: 14.001], pyrrole [FL-no: 14.041] and 2-acetylpyrrole [FL-no: 14.047], the latter also to cover the 
evaluation of the structurally related 2-propionylpyrrole [FL-no: 14.068]. 
Based on the new data submitted (Kojima, 2006) for isoquinoline [FL-no: 14.001] a NOAEL of 3 
mg/kg bw/day could be established. When comparing this NOAEL at step B4 in the Procedure to the 
estimated exposure based on the MSDI (0.012 µg/capita/day, corresponding to 0.0002 µg/kg bw/day) 
an adequate margin of safety of 15 × 106 can be calculated. 
Based on the new data submitted (Marumo, 2008) for pyrrole [FL-no: 14.041] a NOAEL of 3 mg/kg 
bw/day could be established. When comparing this NOAEL at step B4 in the Procedure to the 
estimated exposure based on the MSDI (0.11 µg/capita/day, corresponding to 0.0018 µg/kg bw/day) 
an adequate margin of safety of 16 × 105 can be calculated. 
Based on the new data submitted (Bauter, 2012b) for 2-acetylpyrrole [FL-no: 14.047] a NOAEL of 48 
mg/kg bw/day could be established. When comparing the NOAEL at step B4 in the Procedure to the 
estimated exposure based on the MSDI (3.3 µg/capita/day, corresponding to 0.055 µg/kg bw/day) an 
adequate margin of safety of 87 × 104 can be calculated. For 2-propionylpyrrole [FL-no: 14.068], 
supported by 2-acetylpyrrole [FL-no: 14.047], the MSDI is 0.012 µg/capita/day, which is well below 
the MSDI of 2-acetylpyrrole and accordingly not expected to be of safety concern at the estimated 
levels of intake. 
Additional toxicity data have after the publication of FGE.77Rev1 become available for 1-
furfurylpyrrole [FL-no: 13.134]. The data are intended to cover the re-evaluation of this substance and 
2-acetyl-1-ethylpyrrole [FL-no: 14.045] and 2-acetyl-1-methylpyrrole [FL-no: 14.046]. The main 
study provided is a 90-day study. 
Based on the new data submitted (Kappeler, 2013b) for 1-furfurylpyrrole [FL-no: 13.134], a NOAEL 
of 25 mg/kg bw/day could be established. When comparing this NOAEL at step B4 in the Procedure 
to the estimated exposure based on the MSDI (0.12 µg/capita/day, corresponding to 0.002 µg/kg 
bw/day) an adequate margin of safety of 12.5 × 106 can be calculated. For 2-acetyl-1-ethylpyrrole [FL-
no: 14.045], supported by 1-furfurylpyrrole [FL-no: 13.134], the MSDI is also 0.12 µg/capita/day and 
accordingly not expected to be of safety concern at the estimated levels of intake. For 2-acetyl-1-
methylpyrrole [FL-no: 14.046], the MSDI is 1.2 µg/capita/day which is 10 times the figure for the 
MSDI of 1-furfurylpyrrole resulting in an adequate margin of safety of 12.5 × 105; 2-acetyl-1-
methylpyrrole [FL-no: 14.046] is accordingly not expected to be of safety concern at the estimated 
levels of intake. 
CONCLUSION 
The present Revision of FGE.77, FGE.77Rev2, includes the assessment of additional toxicity data for 
1-furfurylpyrrole [FL-no: 13.134]. The data are intended to cover the re-evaluation of this substance as 
well as 2-acetyl-1-ethylpyrrole [FL-no: 14.045] and 2-acetyl-1-methylpyrrole [FL-no: 14.046]. The 
main study provided is a 90-day study. 
The Panel concluded that the 22 substances in the JECFA flavouring group of pyridine, pyrrole and 
quinoline derivatives are structurally related to the group of pyridine, pyrrole, indole and quinoline 
derivatives from chemical group 28 evaluated by EFSA in the Flavouring Group Evaluation 24, 
Revision 2 (FGE.24Rev2). 
JECFA evaluated two substances [FL-no: 13.134 and 14.030] via the B-side of the Procedure and 20 
substances via the A-side. 
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The Panel agrees with the way the application of the Procedure has been applied by JECFA for four of 
the 22 substances. Three of these four substances, methyl nicotinate [FL-no: 14.071], indole [FL-no: 
14.007] and 3-methylindole [FL-no: 14.004], were evaluated by JECFA on the A-side of the 
Procedure, as they were anticipated to be metabolised to innocuous products. For these three 
substances, EFSA agreed no safety concern at step A3 of the Procedure, as the intake is below the 
threshold of the structural class. For the fourth substance, 2-pyridine methanethiol [FL-no: 14.030], for 
which EFSA agrees with JECFA that it should be evaluated through the B-side of the Procedure, as 
the substance was not anticipated to be metabolised to innocuous products. However, a NOAEL was 
derived from a 90-day study. 
The Panel concluded, contrary to JECFA, that 6-methylquinoline [FL-no: 14.042] (evaluated via the 
B-side by JECFA) should not be evaluated through the Procedure due to concern with respect to 
genotoxicity in vitro. 
Also for 1-furfurylpyrrole [FL-no: 13.134], EFSA disagreed with JECFA, as the 90-day feeding study 
in rats was considered a poorly reported old study, the quality of which cannot be assessed. 
For the remaining 16 substances the Panel, in contrast to JECFA, did not anticipate that they will be 
metabolised to innocuous products and accordingly concluded that they should be evaluated along the 
B-side of the Procedure. However, in FGE.77, for 10 [FL-no: 14.038, 14.039, 14.058, 14.059, 14.060, 
14.061, 14.065, 14.066, 14.072 and 14.164] of these 16 JECFA-evaluated pyridine derivatives 
evaluated via the B-side of the Procedure by EFSA, NOAELs could be derived to provide adequate 
margins of safety and the Panel agrees with the JECFA conclusion “no safety concern at estimated 
levels of intake as flavouring substances” based on the MSDI approach. 
In FGE.77 it was concluded that for pyrrole and the five pyrrole derivatives as well as for isoquinoline 
[FL-no: 13.134, 14.001, 14.041, 14.045, 14.046, 14.047 and 14.068], No Observed Adverse Effect 
Levels (NOAELs) could not be derived as such or for structurally related substances. Accordingly, 
additional toxicological data were required for these seven substances in FGE.77. 
Since publication of FGE.77, three 90-day studies have become available for isoquinoline [FL-no: 
14.001], pyrrole [FL-no: 14.041] and 2-acetylpyrrole [FL-no: 14.047] and NOAELs to provide 
adequate margin of safety are derived to cover these three substances as well as the structurally related 
2-propionylpyrrole [FL-no: 14.068]. 
Since the publication of FGE.77Rev1, one 90-day study has become available for 1-furfurylpyrrole 
[FL-no: 13.134]. An NOAEL to provide adequate margin of safety was derived to cover this substance 
as well as the structurally related 2-acetyl-1-ethylpyrrole [FL-no: 14.045] and 2-acetyl-1-
methylpyrrole [FL-no: 14.046].  
So, in total, for 18 substances [FL-no: 13.134, 14.001, 14.030, 14.038, 14.039, 14.041, 14.045, 14.046, 
14.047, 14.058, 14.059, 14.060, 14.061, 14.065, 14.066, 14.068, 14.072 and 14.164], evaluated via the 
B-side of the Procedure by EFSA, NOAELs could be derived to provide adequate margins of safety. 
For one substance [FL-no: 14.041], the Industry has submitted use levels for normal and maximum 
use. For the remaining 21 substances, use levels are needed to calculate the mTAMDIs in order to 
identify those flavouring substances that need more refined exposure assessment and to finalise the 
evaluation. 
In order to determine whether the conclusion for the 22 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity tests are available for the 22 JECFA- 
evaluated substances. 
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Thus, for one substance, 6-methylquinoline [FL-no: 14.042], the Panel concluded that the Procedure 
should not be applied until adequate genotoxicity data become available. For the remaining 21 JECFA 
evaluated pyridine, pyrrole and quinoline derivatives [FL-no: 13.134, 14.001, 14.004, 14.007, 14.030, 
14.038, 14.039, 14.041, 14.045, 14.046, 14.047, 14.058, 14.059, 14.060, 14.061, 14.065, 14.066, 
14.068, 14.071, 14.072 and 14.164] the Panel agrees with the JECFA conclusion “no safety concern at 
estimated levels of intake as flavouring substances” based on the MSDI approach. 
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SUMMARY OF GENOTOXICITY DATA  
Table 2:  Genotoxicity Data (in vitro / in vivo) JECFA (JECFA, 2006a) 
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
In vitro 
14.007 
1301 
 
Indole 
H
N
 
Reverse mutation S. typhimurium TA100 ≤ 20 µg/plate Negativea (Ochiai et al., 1986) 
Reverse mutation S. typhimurium TM677 4 mmol/l (469 µg/ml)b Negativec (Kaden et al., 1979) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1538 
4 - 2500 µg/plate Negatived (Anderson and Styles, 1978) 
Reverse mutation S. typhimurium TA98, TA100 ≤ 500 nmol/plate  
(59 µg/plate)b 
Negativea (Vance et al., 1986) 
Reverse mutation S. typhimurium TA100, 
TA1535, TA1537 
3 µmol/plate  
(351 µg/plate)b 
Negatived (Florin et al., 1980) 
Reverse mutation S. typhimurium TA98 0.03 - 30 µmol/plate  
(3.5 - 3515 µg/plate)b,e 
Negatived (Florin et al., 1980) 
Reverse mutation S. typhimurium TA97, TA102 10 - 1000 µg/plate Negatived (Fujita et al., 1994) 
Reverse mutation S. typhimurium TA98, TA100 ≤ 0.4 µmol/plate  
(47 µg/plate)b  
Negatived (Sasagawa and Matsushima, 
1991) 
Mutation E. coli WP2 uvrA/pKM101 ≤ 0.4 µmol/plate  
(47 µg/plate)b 
Negatived (Sasagawa and Matsushima, 
1991) 
14.042 
1302 
6-Methylquinoline 
N
 
Reverse mutation S. typhimurium TA100 
 
100 - 600 µg/plate Positivec (Dong et al., 1978) 
Reverse mutation S. typhimurium TA98, TA100 
TA1535, TA1537 
and TA1538 
≤ 3 600 µg/plate Negativea , 
Positivec,f 
(Wild et al., 1983) 
Reverse mutation S. typhimurium TA98 and 
TA100 
≤ 6 µmol/plate  
(859 µg/plate)g 
Negativea 
Positivec 
(Nagao et al., 1977) 
 
Reverse mutation S. typhimurium TA98 and 
TA100 
≤ 1000 µg/plate Negativea 
Positivec 
(Zeiger et al., 1992) 
 
Reverse mutation S. typhimurium TA98 and 
TA100 
NR Negativea 
Positivec 
(Sugimura et al., 1976) 
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Table 2:  Genotoxicity Data (in vitro / in vivo) JECFA (JECFA, 2006a) 
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
Reverse mutation S. typhimurium TA100 5 µmol/plate  
(716 µg/plate)g 
Positivec (Takahashi et al., 1988) 
Reverse mutation S. typhimurium TA98 NR Negatived (Debnath et al., 1992) 
Reverse mutation S. typhimurium TA100 3.3 - 333 µg/plate Negativea 
Positivec 
(Debnath et al., 1992) 
14.001 
1303 
Isoquinoline 
N
 
Reverse mutation S. typhimurium TA98 and 
TA100 
20 - 50 µg/ml Negatived (Sideropoulos and Specht, 
1984) 
Reverse mutation S. typhimurium TM677 ≤ 8 mmol/l  
(1033 µg/ml)h 
Negativec (Kaden et al., 1979) 
Reverse mutation S. typhimurium TA98 and 
TA100 
NR Negatived (Sugimura et al., 1976) 
Reverse mutation S. typhimurium TA98 and 
TA100 
1 - 20 µmol/plate  
(129 - 2583 µg/plate)h 
Negatived (Nagao et al., 1977) 
Reverse mutation S. typhimurium TA98 and 
TA100 
10,000 - 20,000 µg/ml Negatived (Epler et al., 1979) 
 
Mutation E. coli B/r HCR+ 50 µg/ml Negatived (Sideropoulos and Specht, 
1984) 
Unscheduled DNA 
synthesis 
 
Rat hepatocytes NR Negative (Williams, 1984) 
14.004 
1304 
3-Methylindole 
H
N
 
Reverse mutation S. typhimurium TA100, TA1535 
and TA1537 
3 µmol/plate  
(394 µg/plate)i 
 
Negatived (Florin et al., 1980) 
 
Reverse mutation S. typhimurium TA98 0.03 - 30 µmol/plate  
(3.9 - 3935 µg/plate)i 
Negatived,j (Florin et al., 1980) 
Reverse mutation S. typhimurium TA98 and 
TA100 
 
NR Negativec (Kim et al., 1989) 
Reverse mutation S. typhimurium TA98 and 
TA100 
≤ 0.4 µmol/plate  
(52 µg/plate)i 
Negatived (Sasagawa and Matsushima, 
1991) 
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Table 2:  Genotoxicity Data (in vitro / in vivo) JECFA (JECFA, 2006a) 
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
Reverse mutation S. typhimurium TA100 ≤ 100 µg/plate Negativea (Ochiai et al., 1986) 
 
Mutation E. coli WP2 uvrA/pKM101 ≤ 0.4 µmol/plate  
(52 µg/plate)i 
Negatived (Sasagawa and Matsushima, 
1991) 
Mutation E. coli Sd-4-73 0.01 - 0.025 ml/disk Negative (Szybalski, 1958) 
DNA single strand break Bovine kidney cells 10 µmol - 1 mmol/l  
(1.31 - 131.18 µg/ml)i 
Positive (Kim et al., 1989) 
14.047 
1307 
2-Acetylpyrrole 
H
N
O
 
Reverse mutation S. typhimurium TA98 and 
TA100 
12.5 - 200µg/plate Negatived (Wang et al., 1994) 
Reverse mutation S. typhimurium TA98 4 - 100 µmol/plate 
(437 - 10,913 µg/plate)k 
Negativec 
Positivea 
(Lee et al., 1994) 
Reverse mutation S. typhimurium TA100 4 - 100 µmol/plate  
(437 - 10,913µg/plate)k 
Negatived (Lee et al., 1994) 
14.038 
1309 
2-Acetylpyridine 
N
O
 
Mitotic aneuploidy S. cerevisiae D61.M 0.50 - 0.87 % 
(54,000 - 939,600 
µg/ml)l 
Positive (Zimmermann et al., 1986) 
14.041 
1314 
Pyrrole 
H
N
 
Reverse mutation S. typhimurium TA98, TA100 
and TA102 
14 nmol/plate 1.4 
mmol/plate (0.94 - 
93,926 µg/plate)m 
Negatived (Aeschbacher et al., 1989) 
Reverse mutation S. typhimurium TA100, TA1535 
and TA1537 
3 µmol/plate (201 
µg/plate)l 
Negatived (Florin et al., 1980) 
Reverse mutation S. typhimurium TA98 0.03 - 30 µmol/plate  
(2.01 - 2013 µg/plate)m 
Negatived (Florin et al., 1980) 
 
Reverse mutation S. typhimurium TA98 and 
TA100 
NR Negatived (Lee et al., 1994) 
 
Unscheduled DNA 
synthesis 
Rat hepatocytes NR Negative (Williams, 1984) 
14.061 
1315 
3-Ethylpyridine N
 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535 and TA1537 
 
3 µmol/plate  
(321 µg/plate)n 
Negatived (Florin et al., 1980) 
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Table 2:  Genotoxicity Data (in vitro / in vivo) JECFA (JECFA, 2006a) 
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
14.039 
1316 
3-Acetylpyridine 
N
O
 
Mutation E. coli WP2 uvrA 5,000 - 10,000 µg/plate Negative (Pai et al., 1978) 
Mitotic aneuploidy S. cerevisiae D61.M 0.5 - 1.11 %  
(55,100 - 122,322 
µg/ml)o 
 
Positive (Zimmermann et al., 1986) 
In vivo 
14.042 
1302 
6-Methylquinoline 
N
 
Sex-linked recessive 
mutation 
Drosophila melanogaster 10 mmol/l (1432 µg/ml)g 
 
Negative (Wild et al., 1983) 
Micronucleus formation NMRI mouse 0, 286, 429, or 572 
mg/kg bw 
 
Negative (Wild et al., 1983) 
NR: Not reported. 
(a): Without metabolic activation. 
(b): Calculated based on relative molecular mass = 117.15. 
(c): With metabolic activation. 
(d): With and without metabolic activation. 
(e): Toxic at concentrations > 3.0 mmol/plate (351 mg/plate). 
(f): TA100 and TA1535. 
(g): Calculated based on relative molecular mass = 143.19. 
(h): Calculated based on relative molecular mass = 129.16. 
(i): Calculated based on relative molecular mass = 131.18. 
(j): Toxic at concentrations of > 3.0 mmol/plate (394 mg/plate). 
(k): Calculated based on relative molecular mass = 109.13. 
(l): Calculated based on density = 1.08 g/ml (Sigma-Aldrich, 2003; available at http://www.sigmaaldrich.com). 
(m): Calculated based on relative molecular mass = 67.09. 
(n): Calculated based on relative molecular mass = 107.16. 
(o): Calculated based on density = 1.102 g/ml (Sigma-Aldrich, 2003; available at http://www.sigmaaldrich.com). 
Flavouring Group Evaluation 77 Revision 2
 
EFSA Journal 2015;13(1):3997 32 
 
Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.24Rev2 (EFSA CEF Panel, 2013) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
(Pyrrole [14.041]) Ames assay  
(modified 
preincubation 
method) 
S. typhimurium  
TA98; TA100; TA102 
1.4 mmol/plate 
(93926 µg/plate) 
Negative1 (Aeschbacher et al., 
1989) 
  
Ames assay  
(preincubation 
method) 
S. typhimurium  
TA100; TA1535; TA1537 
3 µmol/plate  
(201 µg/plate) 
Negative1 (Florin et al., 1980)   
Ames assay  
(preincubation 
method) 
S. typhimurium  
TA98 
30 µmol/plate 
(2013 µg/plate)  
Negative1   
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Not reported Negative3 (Lee et al., 1994)   
Rec assay B. subtilis 
H17 (rec+), M45 (rec-) 
4 and 20 mg/disk Positive3 (Kim et al., 1987) Poor predictive value for 
mutagenicity. Limited 
value. 
Unscheduled DNA 
synthesis 
Rat hepatocytes Not reported Negative (Williams, 1984)  
1-Methylpyrrole  Ames assay  
(modified 
preincubation 
method) 
S. typhimurium 
TA98; TA100; TA102 
11 nmol – 1.1 
mmol/plate 
Negative1 (Aeschbacher et al., 
1989) 
6 dose levels. The study 
is considered valid. 
Rec assay B. subtilis H17 (rec+) 
M45 (rec-) 
2, 4, 20 and 40 
mg/disk 
(500.5 µmol/disk) 
Positive1 (Kim et al., 1987) Poor predictive value for 
mutagenicity. Limited 
value. 
(Indole [14.007]) Ames assay  
(preincubation 
method) 
S. typhimurium 
TA100 
20 µg/plate Negative2 (Ochiai et al., 1986)  
Ames assay S. typhimurium 
TM677 
4 mM 
(469 µg/ml) 
Negative3 (Kaden et al., 1979)  
Ames assay  
(plate incorporation 
method) 
S. typhimurium  
TA98; TA100; TA1535; TA1538 
2500 µg/plate Negative1 (Anderson and Styles, 
1978) 
 
Ames assay S. typhimurium 
TA98; TA100 
500 nmol/plate 
(59 µg/plate) 
Negative2 (Vance et al., 1986)  
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.24Rev2 (EFSA CEF Panel, 2013) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA100; TA1535; TA1537 
3 µmol/plate 
(351 µg/plate) 
Negative1 (Florin et al., 1980)  
S. typhimurium 
TA98 
30 µmol/plate 
(3515 µg/plate) 
Negative3  
S. typhimurium 
TA97; TA102 
1000 µg/plate Negative1 (Fujita et al., 1994)  
S. typhimurium TA98; TA100 
E. coli WP2uvrA/ pKM101 
0.4 µmol/plate 
(47 µg/plate) 
Negative1 (Sasagawa and 
Matsushima, 1991) 
 
S. typhimurium 
TA100 
500 µg/plate Negative2 (Hashizume et al., 
1991) 
 
2-Methylindole [14.131] Ames assay  
(preincubation 
method) 
S. typhimurium 
TA98; TA100; TA1535; TA1538 
4, 20, 100, 500 and 
2500 µg/plate 
Negative1 (Anderson and Styles, 
1978) 
The study is considered 
valid. 
S. typhimurium 
TA98; TA100; TA1535; TA1537 
3 µmol/plate 
(394 µg/plate) 
Negative1 (Florin et al., 1980) Single dose study. 
Ames assay S. typhimurium 
TA98 
3 nmol - 30 
µmol/plate (12 doses) 
(3935 µg/plate) 
Negative1 (Curvall et al., 1982) The study is considered 
valid. 
S. typhimurium 
TM677 
2 mM 
(262 µg/ml) 
Negative (Kaden et al., 1979) Single dose study. 
(3-Methylindole [14.004]) Ames assay  
(preincubation 
method) 
S. typhimurium 
TA100; TA1535; TA1537 
3 µmol/plate 
(394 µg/plate) 
Negative1 (Florin et al., 1980)  
S. typhimurium 
TA98 
30 µmol/plate 
(3935 µg/plate) 
Negative1 (Florin et al., 1980)  
Ames assay S. typhimurium 
TA98; TA100 
Not reported Negative3 (Kim et al., 1989)  
Ames assay  
(preincubation 
method) 
S. typhimurium TA98; TA100 
E. coli WP2uvrA/ pKM101 
0.4 µmol/plate 
(52 µg/plate) 
Negative1 (Sasagawa and 
Matsushima, 1991) 
 
S. typhimurium 
TA100 
100 µg/plate Negative2 (Ochiai et al., 1986)  
S. typhimurium 
TA100 
Up to 3.33 mM 
(437 µg/ml) 
Negative3 (Reddy et al., 2002)  
Mutation assay  
(paper-disk method) 
E. coli 
Sd-4-73 
0.025 ml/disk Negative (Szybalski, 1958)  
Chromosomal 
aberration assay 
Chinese hamster ovary cells 1.3, 1.4 and 1.5 mM 
(+ S9) 
1.4, 1.5 and 1.6 mM 
Positive1 (Reddy et al., 2002) Aberrations were only 
detected at cytotoxic 
concentrations that 
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.24Rev2 (EFSA CEF Panel, 2013) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
(- S9) showed marked 
inhibition of DNA 
synthesis. 
Alkaline elution 
assay 
Rat primary hepatocytes 
(uninduced and PB/β-NF 
induced) 
0.5, 0.6, 0.7, 0.8, 0.9 
and 1 mM 
Negative (Reddy et al., 2002) The study is considered 
valid. 
DNA modification 
assay 
Isolated human genomic DNA 25 and 500 µM  
(66 µg/ml) 
Positive3 
Negative2 
(Laws et al., 2001) Assay demonstrating 
inhibition of PCR 
amplification and spots 
demonstrated by 
postlabeling. Limited 
predictive value. 
DNA Single strand 
break assay 
Bovine kidney cells 10 µM - 1 mM 
(131.2 µg/ml) 
Positive (Kim et al., 1989) Abstract only. Validity 
cannot be evaluated. 
(2-Acetylpyrrole 
[14.047]) 
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98 
4, 20 and 100 
µmol/plate 
(10913 µg/plate) 
Negative3 
Positive2 
(Lee et al., 1994) 
 
Positive without S9 only 
at the two highest 
concentrations. High 
concentrations. 
Technically acceptable, 
but of limited relevance 
due to high 
concentrations. 
S. typhimurium 
TA100 
100 µmol/plate 
(10913 µg/plate) 
Negative1  
Ames assay S. typhimurium 
TA98; TA100 
Up to 200 µg/plate Negative1 (Wang et al., 1994)  
2-Methylpyridine 
[14.134] 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA98; TA100; TA1535; TA1537 
3 µmol/plate 
(279 µg/plate) 
Negative1 (Florin et al., 1980) Single dose study. 
Ames assay  
(modified 
preincubation 
method) 
S. typhimurium 
TA98; TA100; TA102 
10 nmol - 1 
mmol/plate  
(6 doses) 
(93 µg/ml) 
Negative1 (Aeschbacher et al., 
1989) 
The study is considered 
valid. 
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA97; TA98; TA100; TA102 
Up to 5000 µg/plate  
(6 doses) 
Negative1 (Claxton et al., 1987) Individual dose levels 
not reported. The study 
is considered valid. 
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.24Rev2 (EFSA CEF Panel, 2013) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
S. typhimurium 
TA98; TA100; TA1535; TA1537 
50, 160, 500, 1600 
and 5000 nl/plate  
(4722 µg/plate) 
Negative1 (Vleminckx et al., 
1993a) 
The study is considered 
valid. 
Mitotic aneuploidy 
assay 
S. cerevisiae 
D61.M 
0.5 - 0.74 %  
(6 doses) 
(6988 µg/ml) 
Positive (Zimmermann et al., 
1986) 
Very high doses. The 
effect is considered 
thresholded. Limited 
relevance. 
HGPRT Gene 
mutation assay 
Chinese hamster V79 lung cells 4.5, 4.75, 5, 5.25 and 
5.5 µl/ml  
(5194 µg/ml) 
Negative2 (Vleminckx et al., 
1993b) 
The study is considered 
valid. 
Alkaline elution 
assay 
Chinese hamster V79 lung cells 2, 3, 4, 5 and 6 µl/ml  
(5666 µg/ml) 
Negative2 (Schriewer et al., 1993) The study is considered 
valid. 
3-Methylpyridine[14.135] Ames assay  
(modified 
preincubation 
method)  
S. typhimurium 
TA98; TA100; TA1535; TA1537  
85, 280, 840 and 
8540 µg/plate  
Negative  (Haworth et al., 1983)  The study is considered 
valid. 
Ames assay  
(plate incorporation 
method)  
S. typhimurium 
TA98; TA100; TA1535; TA1537  
50, 160, 500, 1600 
and 5000 nl/plate  
(4785 µg/plate) 
Negative1 (Vleminckx et al., 
1993a) 
The study is considered 
valid. 
Mutagenicity assay  E. coli  
WP2 uvrA  
5 - 10 mg/plate  
(5000 - 10,000 
µg/plate)   
Negative  (Pai et al., 1978)  Single dose study. Very 
few experimental 
details. The validity 
cannot be evaluated. 
HGPRT Gene 
mutation assay 
Chinese hamster 
V79 lung cells  
3, 3.25, 3.5, 3.75 and 
4 µl/ml  
(3828 µg/ml) 
Negative2  (Vleminckx et al., 
1993b) 
The study is considered 
valid. 
Alkaline elution 
assay  
Chinese hamster 
V79 lung cells  
2, 3, 4 and 5 µl/ml  
(4785 µg/ml) 
Negative2 (Schriewer et al., 1993)  The study is considered 
valid. 
4-Methylpyridine 
[14.136] 
Ames assay  
(plate incorporation 
method)  
S. typhimurium 
TA98; TA100; TA1535; TA1537  
50, 160, 500, 1600 
and 5000 nl/plate  
(4779 µg/plate) 
Negative1 (Vleminckx et al., 
1993a)  
The study is considered 
valid. 
HGPRT Gene 
mutation assay 
Chinese hamster 
V79 lung cells  
3.75, 4, 4.25 and 4.5 
µl/ml  
(4301 µg/ml) 
Negative2 (Vleminckx et al., 
1993b)  
The study is considered 
valid. 
Alkaline elution 
assay  
Chinese hamster 
V79 lung cells  
3.75, 4, 4.25 and 4.5 
µl/ml  
Negative2 (Schriewer et al., 1993)  The study is considered 
valid. 
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.24Rev2 (EFSA CEF Panel, 2013) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
(4301 µg/ml) 
(3-Ethylpyridine 
[14.061]) 
Ames assay 
(preincubation 
method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537 
3 µmol/plate  
(321µg/plate) 
Negative1 (Florin et al., 1980) Single dose study. 
2,4-Dimethylpyridine 
[14.104] 
Mitotic aneuploidy 
assay 
S. cerevisiae D61.M 0.4 - 0.60 %  
(6 doses) 
(5551µg/ml) 
Positive (Zimmermann et al., 
1986) 
Very high doses. The 
effect is considered 
thresholded. Limited 
relevance. 
(2,6-Dimethylpyridine 
[14.065]) 
Mitotic  
aneuploidy assay 
S. cerevisiae  
D61.M 
0.5 - 0.60 %  
(4 doses) 
(5551 µg/ml) 
Positive (Zimmermann et al., 
1986) 
Very high doses. The 
effect is considered 
thresholded. Limited 
relevance. 
3,5-Dimethylpyridine 
[14.106] 
Ames assay  
(preincubation 
method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
3 µmol/plate  
(321 µg/plate) 
Negative1 (Florin et al., 1980) Single dose study. 
(2-Acetylpyridine 
[14.038]) 
Ames assay  
(plate incorporation 
method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
100 - 10,000 µg/plate Negative (Longfellow, 1997) Very short summary. 
The results cannot be 
validated. High doses. 
Mouse lymphoma 
assay 
Mouse lymphocytes  
L5178Y tk+/– 
2500 - 4500 µg/ml  
(-S9) 
1000 - 4000 µg/ml 
(+S9) 
Positive1 Very short summary. 
The results cannot be 
validated.  
Mitotic aneuploidy 
assay 
S. cerevisiae  
D61.M 
0.5 - 0.87 %  
(4 doses) 
(9396 µg/ml) 
Positive (Zimmermann et al., 
1986) 
Very high doses. The 
effect is considered 
thresholded. Limited 
relevance. 
(3-Acetylpyridine 
[14.039]) 
Mutation  E. coli  
WP2uvrA 
10000 µg/plate Negative (Pai et al., 1978) Single dose study. Very 
few experimental 
details. The validity 
cannot be evaluated. 
Mitotic aneuploidy 
assay 
S. cerevisiae 
D61.M 
0.5 - 1.11 %  
(5 doses) 
(1223 µg/ml) 
Positive (Zimmermann et al., 
1986) 
Very high doses. The 
effect is considered 
thresholded. Limited 
relevance. 
4-Acetylpyridine [14.089] Ames assay  
(preincubation 
S. typhimurium 
TA97; TA98; TA100; TA102; 
5, 100, 300, 100, 
3000 and 10,000 
Negative1 (Zeiger et al., 1992) The study is considered 
valid. 
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.24Rev2 (EFSA CEF Panel, 2013) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
method) TA104; TA1535; TA1537; 
TA1538 
µg/plate 
Mitotic aneuploidy 
assay 
S. cerevisiae  
D61.M 
0.5 - 1.19 %  
(5 doses) 
(13,114 µg/ml) 
Positive (Zimmermann et al., 
1986) 
Very high doses. The 
effect is considered 
thresholded. Limited 
relevance. 
Mitotic aneuploidy 
assay 
S. cerevisiae 
D61.M 
Up to 11 mg/ml 
 
Positive (Whittaker et al., 1989)  Purity 88 %. Very high 
doses. The effect is 
considered thresholded. 
Limited relevance. 
*: Supporting substances are listed in brackets. 
(1): With and without metabolic activation. 
(2): Without metabolic activation. 
(3): With metabolic activation. 
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Table 4:  Genotoxicity Data (in vivo) EFSA / FGE.24Rev2 (EFSA CEF Panel, 2013) 
Chemical Name [FL-no]* Test System Test Object  Route Dose Result  Reference  Comments 
(3-Methylindole [14.004])* Micronucleus test Mouse Oral  1000 mg/kg day Negative (Reddy et al., 2003) Abstract only. The validity cannot be 
evaluated. 
*: Supporting substance. 
 
 
Table 5:  Genotoxicity Data (in vitro) on 6-Methylquinoline  
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
6-Methylquinoline 
[14.042] 
Chromosomal 
aberration assay 
Chinese hamster ovary 
cells 
52.7, 69.9, 174.8 and 349.5 µg/ml 
50.3, 125.5, 250.9 and 374.5 µg/ml 
Negative (-S9) 
Positive (+S9) 
(NTP, 1986)  
 Sister chromatid 
exchanges 
Chinese hamster ovary 
cells 
16.6, 25.1, 33 and 50 µg/ml 
16.7, 50.1, 166.9 and 500.7 µg/ml 
Positive (-S9) 
Positive (+S9) 
(NTP, 1986)  
 
 
Table 6:  Genotoxicity Data (in vivo) on 6-Methylquinoline  
Chemical Name [FL-no] Test System Test Object  Route Dose Result  Reference  Comments 
6-Methylquinoline [14.042] Micronucleus test Male mouse Gavage 0, 225, 450 and 900 
mg/kg bw 
Negative (Nakajima, 2005) Limited relevance. 
6-Isopropylquinoline Micronucleus test NMRI mouse Oral 0, 500, 1000 and 2000 
mg/ kg bw 
Negative (Honarvar, 2004) Limited relevance. 
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SUMMARY OF TOXICITY DATA 
Table 7:  Toxicity Data Considered by the Panel  
Chemical Name  
[FL-no] 
Species; Sex 
No/group 
Route  Doses 
(mg/kg bw/day) 
Duration 
(days) 
NOAEL 
(mg/kg bw/day) 
Reference  Comments 
Isoquinoline  
[FL-no: 14.001] 
Rat; M, F  
10 
Oral 0, 0.03, 0.3 and 3 90 3 (Kojima, 2006)  It is a GLP study performed according to the 
Japanese “Guidelines for designation of food 
additives and revision of standards for use of food 
additives, Notification No 29” of the 
Environmental Health Bureau, Ministry of Health 
and Welfare, Japan, March 22, 1996. The 
requirements of this guideline are very similar to 
the OECD Guideline 408.  
Pyrrole  
[FL-no: 14.041] 
Rat; M, F  
10 
Gavage 0, 0.03, 0.3 and 3 90 3 (Marumo, 2008) Same as above. 
2-Acetylpyrrole  
[FL-no: 14.047] 
Rat; M, F  
3 
Diet 0, 85, 550 and 842 
(males) 
0, 91, 582 and 949 
(females) 
14 Range-finding (Bauter, 2012a)  
 Rat; M, F  
10 
Diet 0, 68, 133 and 263 
(males) 
0, 79, 155 and 298 
(females) 
90 48 (Bauter, 2012b) Compliant to the OECD guideline (408). 
1-Furfurylpyrrole 
[FL-no: 13.134] 
Rat; M, F  
3 
Diet 0, 29, 84 and 211 
(males) 
0, 27, 81 and 192 
(females) 
14 Range-finding (Kappeler, 2013a)  
 Rat; M, F  
10 
Diet 0, 25, 77 and 154 
(males) 
0, 25, 75 and 151 
(females) 
90 25 (Kappeler, 2013b) Compliant to the OECD guideline (408). 
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SUMMARY OF SAFETY EVALUATIONS 
Table 8:  Summary of Safety Evaluation by JECFA (JECFA, 2005b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI (a)  
US MSDI 
(µg/capita/day) 
Class (b) 
Evaluation procedure path (c) 
Outcome on 
the named 
compound 
[(d) or (e)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
14.004 
1304 
3-Methylindole HN
 
2.4 
0.07 
Class I 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.007 
1301 
Indole HN
 
26 
10 
Class I 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.041 
1314 
Pyrrole HN
 
0.11 
0.01 
Class I 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.038 
1309 
2-Acetylpyridine 
N
O
 
50 
68 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.039 
1316 
3-Acetylpyridine N
O
 
23 
0.8 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.045 
1305 
2-Acetyl-1-ethylpyrrole 
N
O
 
0.12 
0.009 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.046 
1306 
2-Acetyl-1-
methylpyrrole 
N
O
 
1.2 
0.02 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Flavouring Group Evaluation 77 Revision 2
 
EFSA Journal 2015;13(1):3997 41 
Table 8:  Summary of Safety Evaluation by JECFA (JECFA, 2005b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI (a)  
US MSDI 
(µg/capita/day) 
Class (b) 
Evaluation procedure path (c) 
Outcome on 
the named 
compound 
[(d) or (e)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
14.047 
1307 
2-Acetylpyrrole HN
O
 
3.3 
0.2 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.059 
1312 
3-Isobutylpyridine N
 
0.049 
0.07 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.060 
1313 
2-Pentylpyridine N
 
0.061 
0.07 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.061 
1315 
3-Ethylpyridine N
 
9.3 
3 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.065 
1317 
2,6-Dimethylpyridine N
 
0.26 
0.007 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.066 
1318 
5-Ethyl-2-
methylpyridine 
N
 
0.12 
0.04 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.068 
1319 
2-Propionylpyrrole HN
O
 
0.012 
2 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.071 
1320 
Methyl nicotinate N
O
O
 
0.49 
0.2 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.164 
1322 
2-Propylpyridine N
 
0.61 
0.9 
Class II 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
No safety concern at the 
estimated level of intake 
Flavouring Group Evaluation 77 Revision 2
 
EFSA Journal 2015;13(1):3997 42 
Table 8:  Summary of Safety Evaluation by JECFA (JECFA, 2005b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI (a)  
US MSDI 
(µg/capita/day) 
Class (b) 
Evaluation procedure path (c) 
Outcome on 
the named 
compound 
[(d) or (e)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
based on the MSDI 
approach. 
based on the MSDI 
approach. 
14.001 
1303 
Isoquinoline N
 
0.012 
0.07 
Class III 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.042 
1302 
6-Methylquinoline N
 
0.32 
0.01 
Class III 
A3: Intake below threshold 
d Genotoxicity data 
required. 
 
14.058 
1311 
2-Isobutylpyridine N
 
0.0061 
0.9 
Class III 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.072 
1321 
2-(3-
Phenylpropyl)pyridine 
N
 
1.8 
0.7 
Class III 
A3: Intake below threshold 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.134 
1310 
1-Furfurylpyrrole N O
 
0.12 
0.07 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.030 
1308 
2-Pyridine methanethiol SHN
 
0.0012 
0.007 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
(a): EU MSDI: Amount added to food as flavour in (kg / year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365)  =  µg/capita/day. 
(b): Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
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Table 9:  Summary of Safety Evaluation by the EFSA (FGE.24Rev2) (EFSA CEF Panel, 2013) 
FL-no EU Register name Structural formula MSDI a) 
(µg/capita/day) 
Class b) 
Evaluation procedure 
path c) 
Outcome on the 
named compound 
[d) or e)] 
Outcome on the 
material of 
commerce  
[f), g), or h)] 
Evaluation 
remarks 
14.110 
 
Ethyl nicotinate N
O
O
 
0.013 
 
Class II 
A3: Intake below 
threshold 
d f  
14.120 
 
Isopropyl nicotinate N
O
O
 
0.0012 
 
Class II 
A3: Intake below 
threshold 
d f  
14.023 
 
1-Methylpyrrole 
N
 
0.3 
 
Class II 
B3: Intake below 
threshold, B4: No 
adequate NOAEL 
Additional data 
required 
 i 
14.085 
 
2-Acetyl-5-
methylpyrrole 
H
N
O
 
0.0012 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.089 
 
4-Acetylpyridine N
O
 
0.0073 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.092 
 
2-Butylpyridine N
 
0.012 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.093 
 
3-Butylpyridine N
 
0.061 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.103 
 
2,3-Dimethylpyridine N
 
0.037 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
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Table 9:  Summary of Safety Evaluation by the EFSA (FGE.24Rev2) (EFSA CEF Panel, 2013) 
FL-no EU Register name Structural formula MSDI a) 
(µg/capita/day) 
Class b) 
Evaluation procedure 
path c) 
Outcome on the 
named compound 
[d) or e)] 
Outcome on the 
material of 
commerce  
[f), g), or h)] 
Evaluation 
remarks 
14.104 
2151 
2,4-Dimethylpyridine N
 
0.024 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.105 
 
3,4-Dimethylpyridine N
 
0.13 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.106 
 
3,5-Dimethylpyridine N
 
0.073 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.107 
 
2,5-Dimethylpyrrole HN
 
0.061 
 
Class II 
B3: Intake below 
threshold, B4: No 
adequate NOAEL 
Additional data 
required 
 i 
14.115 
 
2-Ethylpyridine N
 
0.027 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.116 
 
4-Ethylpyridine N
 
0.027 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.117 
 
2-Hexylpyridine N
 
0.012 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.118 
 
2-Hydroxypyridine N OH
 
0.024 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
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Table 9:  Summary of Safety Evaluation by the EFSA (FGE.24Rev2) (EFSA CEF Panel, 2013) 
FL-no EU Register name Structural formula MSDI a) 
(µg/capita/day) 
Class b) 
Evaluation procedure 
path c) 
Outcome on the 
named compound 
[d) or e)] 
Outcome on the 
material of 
commerce  
[f), g), or h)] 
Evaluation 
remarks 
14.124 
 
2-Isopropylpyridine 
N
 
0.021 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.125 
 
4-Isopropylpyridine N
 
0.012 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.134 
 
2-Methylpyridine N
 
0.21 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.135 
 
3-Methylpyridine N
 
0.027 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.136 
 
4-Methylpyridine N
 
0.73 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.140 
 
3-Pentylpyridine N
 
0.0012 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.143 
 
3-Propylpyridine N
 
0.0012 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.145 
 
Pyrrole-2-carbaldehyde HN
O
 
0.12 
 
Class II 
B3: Intake below 
threshold, B4: No 
adequate NOAEL 
Additional data 
required 
 j 
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Table 9:  Summary of Safety Evaluation by the EFSA (FGE.24Rev2) (EFSA CEF Panel, 2013) 
FL-no EU Register name Structural formula MSDI a) 
(µg/capita/day) 
Class b) 
Evaluation procedure 
path c) 
Outcome on the 
named compound 
[d) or e)] 
Outcome on the 
material of 
commerce  
[f), g), or h)] 
Evaluation 
remarks 
14.150 
 
2,4,6-Trimethylpyridine N
 
0.012 
 
Class II 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.169 
2150 
1-Ethyl-2-
pyrrolecarboxaldehyde N
O
 
0.12 
 
Class II 
B3: Intake below 
threshold, B4: No 
adequate NOAEL 
Additional data 
required 
 j 
13.100 
 
2-Acetyl-1-
furfurylpyrrole 
N
O
O
 
0.091 
 
Class III 
B3: Intake below 
threshold, B4: No 
adequate NOAEL 
Additional data 
required 
 i 
14.088 
 
1-Acetylindole 
N
O
 
0.0012 
 
Class III 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.131 
 
2-Methylindole HN
 
0.0012 
 
Class III 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f  
14.163 
2152 
1-Methylpyrrole-2-
carboxaldehyde 
N
O
 
0.0024 
 
Class III 
B3: Intake below 
threshold, B4: No 
adequate NOAEL 
Additional data 
required 
 j 
14.002 
 
4-Methylquinoline N
 
0.12 
 
Class III 
No evaluation 
  i 
14.094 
 
4-Butylquinoline N
 
0.0012 
 
Class III 
No evaluation 
  i 
14.138 
 
2-Methylquinoline N
 
0.012 
 
Class III 
No evaluation 
  i 
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(a): EU MSDI: Amount added to food as flavour in (kg / year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365)  =  µg/capita/day. 
(b): Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f): No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or 
information on stereoisomerism. 
(h): No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
(i): No longer supported by Industry (DG SANCO, 2012). 
(j): No longer supported by Industry (DG SANCO, 2013). 
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DOCUMENTATION PROVIDED TO EFSA 
1. Bauter MR, 2012b. Draft Report. 2-Acetylpyrrole: A 90-day dietary study in rats. Product Safety 
Labs. Study no. 33327. Marts 2, 2012. Unpublished report submitted by EFFA to FLAVIS 
Secretariat. 
2. DG SANCO (Directorate General for Health and Consumer Affairs), 2012. Information from DG 
SANCO 07/02 2012, concerning two lists of 85 and 15 non-supported substances and one list of 
30 substances for which no data have been submitted or which are duplicates. FLAVIS.2.23rev1. 
3. DG SANCO (Directorate General for Health and Consumer Affairs), 2013. Information from DG 
SANCO 14/05 2013, concerning a list of 18 non-supported substances. FLAVIS.2.26. 
4. EFFA (European Flavour Association), 2012. Addendum of Additional Data Relevant to the 
Flavouring Group Evaluation of the Chemical Group 28 (Annex I of 1565/2000/EC) Pyridine, 
Pyrrole, Indole and Quinoline Derivatives [JECFA/WHO FAS 63] Used as Flavouring 
Substances. June 2012. FLAVIS/8.163. 
5. Honarvar N, 2004. Final report. Micronucleus assay in bone marrow cells of the mouse with 
BASE 3. RCC-Cytotest Cell Research GmbH. Study no. 809103. February 23, 2004. Unpublished 
report submitted by EFFA to FLAVIS Secretariat. 
6. Kappeler KV, 2013a. A 14-Day Oral (Dietary) Toxicity Study of 1-Furfurylpyrrole in Rats. WIL 
Research. Study no. WIL-968003. 23 July 2013. Unpublished report submitted by EFFA to 
FLAVIS Secretariat. 
7. Kappeler KV, 2013b. A 90-Day Oral (Dietary) Toxicity Study of 1-Furfurylpyrrole in Sprague 
Dawley Rats. WIL Research. Study no. WIL-968004. 15 April 2013. Unpublished report 
submitted by EFFA to FLAVIS Secretariat. 
8. Kojima K, 2006. [Studies or tests for the standards for foods, foods additives, etc. 90-Day repeated 
oral dose toxicity study of isoquinoline in rats]. Hatano Research Institute, Food and Drug Safety 
Center, Japan. Study No. C-06-010. Unpublished report submitted by EFFA to FLAVIS 
Secretariat. [In Japanese - English translation included] 
9. Marumo H, 2008. 90-day repeated oral dose toxicity study of pyrrole in rats. Final report. Hatano 
Research Institute, Food and Drug Safety Center. Study no. C-06-009. January 25, 2008. 
Unpublished report submitted by EFFA to FLAVIS Secretariat. 
10. Mendes O, 2012. Draft Report. 2-Acetylpyrrole: A 10-day oral metabolism/toxicity study in rats. 
Product Safety Labs. Study no. 34496. June 11-21, 2012. Unpublished report submitted by EFFA 
to FLAVIS Secretariat. 
11. Morgareidge K, 1971. 90-Day feeding study with N-furfurylpyrrole in rats. Food and Drug 
Research Laboratories. February 12, 1971. Unpublished report submitted by EFFA to FLAVIS 
Secretariat. 
12. Nakajima Y, 2005. In vivo micronucleus study in mice. 6-Methylquinoline. Experiment No: 8818- 
079-254. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
13. Schriewer L, Vleminckx C, Rigaux G, Ottogali M and Lakhanisky T, 1993. Evaluation of the 
genotoxic potential of pyridine and methylated pyridines. Pyridine, 2-methylpyridine, 3-
methylpyridine, 4-methylpyridine. C. DNA single-stranded breaks measurement in V79 cells. 
Reilly Industries. Institute of Hygiene and Epidemiology. Vleminckx, C. Study no. IHE-TOX-
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1003. EPA Doc 86-930000182, microfiche no. OTS0538163. Unpublished report submitted by 
EFFA to FLAVIS Secretariat. 
14. Til HP and van der Meulen HC, 1971. Subchronic (90-day) toxicity study with 2-acetylpyridine in 
albino rats. Centraal Instituut Voor Voedingsonderzioek, Netherlands. Report no. R3373. 
February, 1971. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
15. Vleminckx C, Ottogali M, Schriewer L, Rigaux G and Lakhanisky T, 1993a. Evaluation of the 
genotoxic potential of pyridine and methylated pyridines. Pyridine, 2-methylpyridine, 3-
methylpyridine, 4-methylpyridine. A. Salmonella/microsome test. Reilly Industries with cover 
letter dated 03/29/93. Study no. IHE-TOX-1003. Date 3/29/93. EPA Doc. 86-930000180, 
microfiche no. OTS0538163. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
16. Vleminckx C, Rigaux G, Schriewer L, Ottogali M and Lakhanisky T, 1993b. Evaluation of the 
genotoxic potential of pyridine and methylated pyridines. Pyridine, 2-methylpyridine, 3-
methylpyridine, 4-methylpyridine. B. HGPRTgene mutation assay in V79 cells. Reilly Industries. 
Study no. IHE-TOX-1003. EPA Doc. 86-930000181, microfiche no. OTS0538163. Unpublished 
report submitted by EFFA to FLAVIS Secretariat. 
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APPENDIX 
Appendix A.  Exposure Data 
Table 10:  Normal and Maximum use levels available for substances in FGE.77Rev2 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
14.041 3 
3 
- 
- 
3 
3 
- 
- 
- 
- 
3 
3 
3 
3 
3 
3 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0 
0 
0 
0 
- 
- 
- 
- 
 
Table 11:  Estimated intakes based on the MSDI- and the mTAMDI12 approach – FGE.77Rev2 
FL-no EU Register name MSDI – EU 
(µg/capita/day) 
MSDI – USA 
(µg/capita/day) 
mTAMDI 
(µg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
14.004 3-Methylindole 2.4 0.07  Class I 1800 
14.007 Indole 26 10  Class I 1800 
14.041 Pyrrole 0.11 0.01 480 Class I 1800 
14.038 2-Acetylpyridine 50 68  Class II 540 
14.039 3-Acetylpyridine 23 0.8  Class II 540 
14.045 2-Acetyl-1-ethylpyrrole 0.12 0.009  Class II 540 
14.046 2-Acetyl-1-methylpyrrole 1.2 0.02  Class II 540 
14.047 2-Acetylpyrrole 3.3 0.2  Class II 540 
14.059 3-Isobutylpyridine 0.049 0.07  Class II 540 
14.060 2-Pentylpyridine 0.061 0.07  Class II 540 
14.061 3-Ethylpyridine 9.3 3  Class II 540 
14.065 2,6-Dimethylpyridine 0.26 0.007  Class II 540 
14.066 5-Ethyl-2-methylpyridine 0.12 0.04  Class II 540 
14.068 2-Propionylpyrrole 0.012 2  Class II 540 
14.071 Methyl nicotinate 0.49 0.2  Class II 540 
14.164 2-Propylpyridine 0.61 0.9  Class II 540 
                                                     
12
 For the calculation of mTAMDI – see e.g. Annex II in FGE.03 (EFSA, 2004). 
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Table 11:  Estimated intakes based on the MSDI- and the mTAMDI12 approach – FGE.77Rev2 
FL-no EU Register name MSDI – EU 
(µg/capita/day) 
MSDI – USA 
(µg/capita/day) 
mTAMDI 
(µg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
14.001 Isoquinoline 0.012 0.07  Class III 90 
14.042 6-Methylquinoline 0.32 0.01  Class III 90 
14.058 2-Isobutylpyridine 0.0061 0.9  Class III 90 
14.072 2-(3-Phenylpropyl)pyridine 1.8 0.7  Class III 90 
13.134 1-Furfurylpyrrole 0.12 0.07  Class III 90 
14.030 2-Pyridine methanethiol 0.0012 0.007  Class III 90 
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ABBREVIATIONS 
bw  Body Weight 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EFSA  The European Food Safety Authority 
EPA  United States Environmental Protection Agency 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations 
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation 
FLAVIS (FL)  Flavour Information System (database) 
GLP   Good Laboratory Practise 
GC-MS  Gas chromatography-mass spectrometry 
ID  Identity 
I.p.   Intraperitoneal 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MSDI   Maximised Survey-derived Daily Intake 
mTAMDI  Modified Theoretical Added Maximum Daily Intake 
NCE   Normochromatic erythrocyte 
No   Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCE  Polychromatic erythrocyte 
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PCR  Polymerase Chain Reaction 
SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
WHO  World Health Organization 
